WO1998032880A1 - Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries - Google Patents
Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries Download PDFInfo
- Publication number
- WO1998032880A1 WO1998032880A1 PCT/US1998/001196 US9801196W WO9832880A1 WO 1998032880 A1 WO1998032880 A1 WO 1998032880A1 US 9801196 W US9801196 W US 9801196W WO 9832880 A1 WO9832880 A1 WO 9832880A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ribozyme
- nucleic acid
- cells
- cell
- gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 296
- 239000013598 vector Substances 0.000 title claims abstract description 140
- 108090000994 Catalytic RNA Proteins 0.000 title claims description 452
- 238000010230 functional analysis Methods 0.000 title description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 152
- 230000014509 gene expression Effects 0.000 claims abstract description 75
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 73
- 230000007017 scission Effects 0.000 claims abstract description 61
- 108090001052 hairpin ribozyme Proteins 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 46
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 466
- 108091092562 ribozyme Proteins 0.000 claims description 384
- 102000053642 Catalytic RNA Human genes 0.000 claims description 381
- 150000007523 nucleic acids Chemical class 0.000 claims description 259
- 102000039446 nucleic acids Human genes 0.000 claims description 242
- 108020004707 nucleic acids Proteins 0.000 claims description 242
- 238000000034 method Methods 0.000 claims description 157
- 108700008625 Reporter Genes Proteins 0.000 claims description 51
- 238000009739 binding Methods 0.000 claims description 48
- 230000027455 binding Effects 0.000 claims description 47
- 238000000338 in vitro Methods 0.000 claims description 46
- 241001465754 Metazoa Species 0.000 claims description 45
- 238000010367 cloning Methods 0.000 claims description 37
- 239000000523 sample Substances 0.000 claims description 35
- 230000009261 transgenic effect Effects 0.000 claims description 34
- 230000001413 cellular effect Effects 0.000 claims description 33
- 238000001727 in vivo Methods 0.000 claims description 28
- 239000000758 substrate Substances 0.000 claims description 28
- 238000004806 packaging method and process Methods 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 22
- 108020004999 messenger RNA Proteins 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 19
- 108091034117 Oligonucleotide Proteins 0.000 claims description 18
- 238000009396 hybridization Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 230000002463 transducing effect Effects 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 16
- 108010092277 Leptin Proteins 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 229910052749 magnesium Inorganic materials 0.000 claims description 11
- 230000035945 sensitivity Effects 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 9
- 210000000349 chromosome Anatomy 0.000 claims description 8
- 210000004602 germ cell Anatomy 0.000 claims description 7
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 108091008039 hormone receptors Proteins 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- 108010065556 Drug Receptors Proteins 0.000 claims description 3
- 102000013138 Drug Receptors Human genes 0.000 claims description 3
- 108700005075 Regulator Genes Proteins 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 210000002308 embryonic cell Anatomy 0.000 claims description 2
- 230000009395 genetic defect Effects 0.000 claims 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 74
- 235000018102 proteins Nutrition 0.000 description 71
- 108020004414 DNA Proteins 0.000 description 65
- 239000000047 product Substances 0.000 description 61
- 238000003752 polymerase chain reaction Methods 0.000 description 50
- 239000013615 primer Substances 0.000 description 40
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 29
- 108700019146 Transgenes Proteins 0.000 description 24
- 238000003018 immunoassay Methods 0.000 description 23
- 241000700605 Viruses Species 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 22
- 230000001177 retroviral effect Effects 0.000 description 22
- 238000013518 transcription Methods 0.000 description 22
- 230000035897 transcription Effects 0.000 description 21
- 230000002163 immunogen Effects 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 239000013607 AAV vector Substances 0.000 description 18
- 238000001415 gene therapy Methods 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 238000010361 transduction Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 239000003550 marker Substances 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 230000026683 transduction Effects 0.000 description 15
- 241000701161 unidentified adenovirus Species 0.000 description 15
- 230000003321 amplification Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 241000251131 Sphyrna Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000003197 catalytic effect Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 230000010354 integration Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 108010053770 Deoxyribonucleases Proteins 0.000 description 11
- 102000016911 Deoxyribonucleases Human genes 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 11
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000002853 nucleic acid probe Substances 0.000 description 10
- 239000013608 rAAV vector Substances 0.000 description 10
- 108700020796 Oncogene Proteins 0.000 description 9
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 238000012552 review Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 7
- 102000016267 Leptin Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 108091005461 Nucleic proteins Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 238000011109 contamination Methods 0.000 description 7
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 7
- 229940039781 leptin Drugs 0.000 description 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- 102000043276 Oncogene Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108020003215 DNA Probes Proteins 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 206010038997 Retroviral infections Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 108091092328 cellular RNA Proteins 0.000 description 4
- 230000009137 competitive binding Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 229940127073 nucleoside analogue Drugs 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 206010001258 Adenoviral infections Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101150003028 Hprt1 gene Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241000710961 Semliki Forest virus Species 0.000 description 3
- 241000710960 Sindbis virus Species 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 101150003725 TK gene Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000001109 blastomere Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000012215 gene cloning Methods 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 230000009452 underexpressoin Effects 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100033407 Alpha-amylase 2B Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 101000732641 Homo sapiens Alpha-amylase 2B Proteins 0.000 description 2
- 101000693011 Homo sapiens Pancreatic alpha-amylase Proteins 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012296 in situ hybridization assay Methods 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000006151 minimal media Substances 0.000 description 2
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- -1 promoters Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 108010051423 streptavidin-agarose Proteins 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical compound N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- OBULAGGRIVAQEG-DFGXMLLCSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21.O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 OBULAGGRIVAQEG-DFGXMLLCSA-N 0.000 description 1
- CNNSWSHYGANWBM-UHFFFAOYSA-N 6-chloro-2,3-dimethylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(C)C(C)=NC2=C1 CNNSWSHYGANWBM-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100025907 Dyslexia-associated protein KIAA0319-like protein Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 101000597041 Gallus gallus Transcriptional enhancer factor TEF-3 Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108091027874 Group I catalytic intron Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001076904 Homo sapiens Dyslexia-associated protein KIAA0319-like protein Proteins 0.000 description 1
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
- 101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101100446031 Mus musculus Fabp4 gene Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000248384 Tetrahymena thermophila Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 102000014823 calbindin Human genes 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 101150039352 can gene Proteins 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 101150055276 ced-3 gene Proteins 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 101150090192 how gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004939 midgestation embryo Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Definitions
- This invention relates generally to methods for using hairpin ribozymes to inactivate target RNA molecules.
- the present invention specifically provides methods for identifying, isolating, and characterizing unknown genes and gene products responsible for detectable phenotypic traits or for characterizing unknown phenotypic effects of known genes, and methods of inactivating target RNAs.
- the hairpin ribozyme has been discovered to be uniquely effective as a randomized antisense tool.
- a ribozyme is an RNA molecule that catalytically cleaves other RNA molecules.
- Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNAse P, and axhead ribozymes. See Castanotto et al. (1994) Advances in Pharmacology 25:289-317 for a general review of the properties of different ribozymes.
- hairpin ribozymes are described e.g. , in Hampel et a ⁇ . (1990) Nucl. Acids Res. 1 8:299-304; Hampel et al. (1990) European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678, issued October 1 9, 1 993; Wong-Staal et al., WO 94/26877; Ojwang et al. (1993) Proc. Natl. Acad. Sci. USA 90:6340-6344; Yamada et al. (1994) Human Gene Therapy 1:39-45; Leavitt et al. (1995) Proc. Natl. Acad. Sci.
- Hairpin ribozymes typically cleave one of two target sequences, NNNNN*GUCNNNNNN or NNNNN*GUANNNNNNNN (* denotes the cleavage site, and N can be any nucleotide). See, De Young et al. (1995) Biochemistry 34: 1 5785-1 5791 .
- the products of the cleavage reaction are a 5' fragment terminating in a 2', 3' cyclic phosphate and a 3' fragment bearing a newly formed 5'-OH.
- the reaction is reversible; ribozymes also catalyze the formation of phosphodiester bonds. See generally, Buzayan et al. (1986) Nature 323:349-352; Gerlach et al. (1986) Virology 1 51 : 1 72-1 85; Hampel et al. (1989) Biochemistry 28:4929-4933; Gerlach et al. (1989) Gene 82:43-52; Feldstein et al. (1989) Gene 82:53-61 ; and Hampel et al. Australian Patent No. AU-B-41 594/89.
- Ribozymes can be used to engineer RNA molecules prior to reverse transcription and cloning, in a manner similar to the DNA endonuclease "restriction" enzymes.
- the production of specific ribozymes which target particular sequences is taught in the art ⁇ see, e.g. , Yu et al. (1993) Proc. Natl. Acad. Sci. USA 90:6340-6344 and Dropulic er a/. (1992) J. Virol. 66(3): 1432-1441 ; Wong-Staal et a/., WO 94/26877).
- Ribozymes which cleave or ligate a particular RNA target sequence can be expressed in cells to prevent or promote expression and translation of RNA molecules comprising the target sequence.
- expression of hairpin ribozymes which specifically cleave human immunodeficiency (HIV) RNAs prevent replication of the virus in cells.
- HAV human immunodeficiency
- a hammerhead ribozyme library comprising a randomized recognition sequence was used for in vitro selection of ribozymes which actively cleave a specific target RNA (Lieber and Strauss (1995) Mol. Cell. Biol. 1 5:540-551 ; patent publication 96/01314); ribozymes selected by this method were then expressed in tissue culture cells (id.) and in transgenic mice (Lieber and Kay (1996) J. Virol. 70:3153-3158).
- hammerhead ribozyme libraries comprising a randomized catalytic region have been used to select ribozymes that efficiently cleave a specific target RNA. Patent publication WO 92/01806.
- the target site may be hidden within the folds of secondary structure in the substrate RNA, or by interaction with RNA binding molecules
- the substrate RNA and the ribozyme may not be present in the same cellular compartment
- the ribozyme may be inhibited or inactivated in vivo, either because it is degraded, or because it assumes a secondary structure in vivo that is incompatible with catalytic activity, or because of interactions with cellular molecules.
- the observed biological effects in some instances can be attributed to simple binding of the ribozyme, as opposed to binding and cleavage,
- the ribozyme is not produced in sufficient quantities.
- the present invention addresses these and other problems.
- a hairpin ribozyme gene library having a randomized target recognition sequence, packaged in a vector which is suitable for high level transduction and expression in a wide variety of cells is used to identify, isolate, and characterize unknown genes and gene products responsible for detectable phenotypic traits, and to characterize unknown phenotypic effects of known genes.
- the vector is an adeno-associated virus vector (AAV).
- AAV adeno-associated virus vector
- the ribozyme gene is preferably operably linked to a transcriptional promoter that allows for optimal inhibition of target RNA expression in vivo, such as a pol III promoter. The result is an unexpectedly high level of expression of the ribozyme gene products. This efficient expression in turn makes possible the in vivo or in vitro selection of ribozyme genes that are active in vivo, even when the target site is not known.
- the invention comprises a method of correlating expression of a nucleic acid that encodes a hairpin ribozyme with the appearance or loss of a detectable phenotype which results from the inhibition or expression of a cellular gene not previously known to result in said phenotype, which involves generating transduced cell clones which express at least one reporter gene or otherwise selectable marker and one or more ribozyme genes from a library of hairpin ribozyme-encoding nucleic acids having randomized target recognition sequences, detecting a phenotypic difference between a transduced cell that expresses said hairpin ribozyme, and a cell of the parental cell line that does not express said hairpin ribozyme, deconvoluting if necessary, isolating and sequencing the ribozyme present in transduced cells that express a selected phenotype.
- the hairpin ribozyme-encoding nucleic acid is operably linked to an inducible or constitutive promoter.
- the cells can be eukaryotic, particularly mammalian cells, and the cellular gene can be from the genome of the transformed cell.
- the invention comprises a method of determining unknown phenotypic effects of a coding nucleic acid of known sequence, comprising: simultaneously expressing within a same cell a coding nucleic acid of known sequence and also a hairpin ribozyme that recognizes at least one GUC site present in said coding nucleic acid of known sequence; and then detecting phenotypic differences between cells that simultaneously express said coding nucleic acid of known sequence and also a hairpin ribozyme that recognizes said at least one GUC site present in said coding nucleic acid of known sequence, and cells that express only said coding nucleic acid of known sequence, or cells that express only said hairpin ribozyme that recognizes a GUC site present in said coding nucleic acid of known sequence.
- the invention comprises a method of identifying a nucleic acid whose gene product mediates binding to a selected ligand, comprising transducing a population of parental ceils which express a nucleic acid whose gene product mediates binding to a selected ligand with vectors that comprise a library of hairpin ribozyme-encoding nucleic acids having randomized recognition sequences and with a nucleic acid that encodes at least one reporter gene; identifying and cloning a transduced cell that does not bind to said selected ligand, to yield a population of cloned cells that do not bind to said selected ligand; isolating the ribozyme that is expressed in said cloned transduced cells; and determining the sequence of the recognition sequence of the ribozyme; making an oligonucleotide probe consisting of the recognition sequence of the ribozyme; and identifying a nucleic acid whose gene product is recognized by the ribozyme using the
- the selected ligand may be one that binds to a cell surface receptor.
- the ligand may be present on a viral particle, a growth factor, a differentiation factor, any protein with an antibody directed against it. It can be identified by FACS or affinity separation techniques.
- the ligand may belong to the group consisting of hormone receptors, receptors for molecules that induce apoptosis, and drug receptors.
- the invention comprises a method of identifying regulatory gene products and genes that control the expression of a particular selected nucleic acid, by genetically engineering a population of cells to express in every cell a selected gene operably linked to one or more reporter genes in a vector and at least one member of a library of hairpin ribozyme-encoding nucleic acids having randomized recognition sequences; isolating and cloning a genetically engineered cell wherein the level of expression of the reporter gene is measurably different from that of ceils that express the reporter gene but do not express a member of said library of hairpin ribozyme-encoding nucleic acids; and identifying a nucleic acid whose gene product is recognized by a ribozyme expressed in the cloned genetically engineered cells.
- the invention comprises a method of identifying a gene whose gene product confers sensitivity to a selected chemical compound or sensitivity to a cytolytic virus or any other microbial entity, comprising transducing a population of parental cells which are sensitive to a selected chemical compound or virus or microbe with vectors that comprise a library of hairpin ribozyme-encoding nucleic acids having randomized recognition sequences; identifying and cloning a transduced cell that is resistant to said selected chemical compound or virus or microbe, to yield a population of cloned transduced cells that are resistant to said selected chemical compound or virus or microbe; and identifying a nucleic acid whose gene product is recognized by a ribozyme expressed by the cloned transduced cells of step b.
- the invention comprises a method of identifying a gene whose gene product confers sensitivity to a non-cytolytic virus, comprising transducing a population of parental cells which are sensitive to a selected virus with vectors that comprise a library of hairpin ribozyme-encoding nucleic acids having randomized recognition sequences; identifying and cloning a transduced cell that is resistant to said virus.
- Resistant cells can be identified by sorting for those cells that lack expression of a viral antigen (ideally a cell surface associated antigen) following infection.
- cells expressing ribozymes can be selected based on their ability to inactivate expression of one or more viral promoters through the inactivation of viral or cellular genes necessary for transactivation or transexpression of the viral promoter, by linking a selectable marker to the viral promoter and selecting for the loss of reporter gene function.
- the invention comprises the generation of a target nucleic acid and an in vitro method of detecting a ribozyme that cleaves said target, comprising hybridizing a library of hairpin ribozyme-encoding nucleic acids having randomized recognition sequences in vitro to a target nucleic acid (RNA or DNA that has been converted to RNA) under stringent hybridization conditions in a solution that does not permit cleavage, wherein the ribozymes having recognition sequences that are complementary to the target nucleic acid hybridize to the recognition site on the target nucleic acid but do not cleave the target nucleic acid; and collecting one or more ribozymes that bind to the target nucleic acid.
- the target nucleic acid is preferably attached to a solid substrate and consists of RNA or DNA that has been converted to RNA, and can be derived from an isolated chromosome, an isolated nucleic acid that encodes a desired gene product, a selected isolated nucleic acid fragment; an isolated pol ⁇ cistronic nucleic acid; a cDNA library, and a total messenger RNA fraction of a cell.
- ribozymes with activity against said target can be amplified and the selection procedure can be repeated multiple times.
- the target nucleic acid is not attached to a solid support and the trans-ligation properties of the hairpin ribozyme are employed to "tag" the cleavage products. This ribozyme "tag” is then used to amplify the specific active ribozymes.
- the invention comprises a method for identifying differentially-expressed genes between two cell types, using in vitro selection techniques that are technically easier than currently available methods. Further, the invention comprises identifying a ribozyme or ribozymes that will inactivate the differentially-expressed gene(s).
- the invention comprises an in vivo method of selecting at least one hairpin ribozyme gene that cleaves a target recognition site in a target nucleic acid, comprising generating cells that co-express a library of hairpin ribozyme-encoding nucleic acids having randomized recognition sequences and a nucleic acid that encodes at least one FACS-sortable or otherwise selectable reporter gene, wherein the gene product of at least one ribozyme-encoding nucleic acid cleaves a target sequence in a selected target nucleic acid; isolating and packaging the ribozyme-encoding nucleic acids of said cloned cells; then generating and cloning transduced cells that express at least one ribozyme-encoding nucleic acid whose gene product cleaves a target sequence; and isolating the ribozyme-encoding nucleic acid from the cloned cells.
- the invention comprises a method for identifying genes involved in cancer formation, such as oncogenes or tumor suppressors.
- This comprises transducing parental cells with vectors that comprise a library of hairpin ribozyme-encoding nucleic acids having randomized recognition sequences; identifying and cloning a transduced ceil that has either: a) in the case of oncogenes, lost its transforming potential in tissue culture and nude mice or b) gained transformation capabilities in tissue culture and nude mice, as would be the case for loss of tumor suppressor function.
- the invention comprises a method of detecting a ribozyme that produces a detectable phenotype in a mammal, comprising generating transgenic or chimeric non-human mammals that express nucleic acids that encode hairpin ribozymes that recognize a selected target nucleic acid; screening transgenic mammals for a selected phenotype; and isolating and characterizing the ribozyme-encoding nucleic acids from the cells of the transgenic or chimeric animal.
- the phenotype is a neurological disorder, such as Alzheimer's disease (Games et al. (1995) Nature 373:523; Moran et al. (1995) PNAS USA 92:5341 ).
- the invention comprises a target- specific ribozyme gene library, generated by collecting ribozymes that bind to and cleave a specific target sequence.
- the invention comprises a differential cell ribozyme gene library, composed of ribozymes that bind to a first cell line but not to a second cell line.
- the invention comprises a kit which includes a hairpin ribozyme library having a randomized recognition sequence, packaged in a vector which is suitable for high level expression in a wide variety of cells.
- the preferred vector is an adenoviral associated vector, and the ribozyme gene is preferably operably linked to a pol III promoter.
- the kit further comprises reagents and detailed instruction for use in the above methods of the invention.
- Figure 1 The hairpin ribozyme.
- the hairpin ribozyme consists of a 50 to 54 nucleotide RNA molecule (shaded, in uppercase letters) which binds and cleaves an RNA substrate (lowercase letters).
- the catalytic RNA folds into a 2-dimensional structure that resembles a hairpin, consisting of two helical domains (Helix 3 and 4) and 3 loops (Loop 2, 3 and 4). Two additional helixes, Helix 1 and 2, form between the ribozyme and its substrate.
- the length of Helix 2 is fixed at 4 basepairs and the length of Helix 1 typically varies from 6 to 10 basepairs.
- the substrate must contain a GUC in Loop 5 for maximal activity, and cleavage occurs immediately 5' of the G as indicated by an arrow.
- the catalytic, but not substrate binding, activity of the ribozyme can be disabled by mutating the AAA in Loop 2 to CGU.
- Figure 2 Cleavage of target substrates by hairpin ribozyme library.
- purified ribozyme was added at the concentration expected to be found in the library
- the cleavage pattern between the purified ribozyme and the ribozyme library is identical when the same RNA substrate is used (HIV 1 , ribozyme vs. ribozyme library).
- FIG. 3 AAV plasmid (pAMFT-dBam).
- Genomic organization of pAMFT.dBam a recombinant plasmid from which infectious adeno-associated viral vector (rAAV) harboring an expression cassette for a hairpin ribozyme can be produced.
- the major components of this plasmid are: AAV 5'-ITR (inverted terminal repeat), neomycin resistance gene, hairpin ribozyme gene (denoted U5 in figure) under control of tRNA val pol III promoter, AAV 3'-ITR.
- Figure 4 Generation of rAAV-ribozyme library pro-vector by PCR.
- FIG. 1 A schematic illustration showing how full length rAAV constructs containing the ribozyme library genes can be generated by two rounds of PCR.
- the resulting linear DNA can be re-ligated via the Bgl II restriction enzyme sites flanking the whole rAAV genome.
- FIG. 5 Production scheme for AAV.
- Figure 6 Concept of cloning genes using AAV-ribozyme library.
- Cells are transduced with the AAV-ribozyme library such that each cell expresses one or more ribozymes from the library.
- the particular phenotype in question is screened and selected for. Positive clones are used to rescue the rAAV responsible followed by re-infection and screening. Once selection is complete, the ribozyme gene is rescued, its activity is confirmed and its sequenced. The deduced sequence is used to prepare a unique DNA probe to clone the target gene.
- Figure 7 Attaching RNA target to solid support.
- Target RNA can be immobilized on solid supports by a variety of methods, by either their 5' or 3' ends. Details are described in the text.
- Figure 8 In vitro selection of efficient ribozymes.
- Splinkerette assay indicates rAAV is integrating site-specifically in the host cell genome following transduction. Molt 4/8 cells were transduced by AAV AMFT or AMY2 as indicated and selected in G418 until a stable G418 resistant population emerged. DNA was then isolated from uncloned cells and 1 ug DNA was digested with a restriction enzyme that does not cut in the vector so that unintegrated DNA would not be detected. DNA was digested with Bgl II and iigated to oligonucleotide splinkerettes comparable to those previously described (Devon et al. (1995) Nucleic Acids Res. 23: 1 644).
- AMFT.1 and AMFT.2 are separate transductions with the same vector (AMFT).
- Figure 10 Schematic of trans cleavage and li ⁇ ation.
- Auto-catalytic ribozyme library is transcribed in vitro and allowed to self-cleave. Self-cleaved, helix 2-charged ribozymes are purified and incubated with the target RNA. Following cleavage of target, a portion of the charged ribozymes will ligate themselves to the cleavage products. These product-ribozyme species are then amplified by reverse transcription and PCR to yield the target specific ribozymes.
- Recombinant AAV preparations with high titers were obtained from current CsC ⁇ purification procedure.
- the producer cells were lysed with the non-ionic detergent octylglucoside or the ionic detergent deoxycholate q rather than the freeze-thaw procedure used previously.
- High titer (5 x 10 ⁇
- Table 5 Optimization of glyceroi storage conditions for rAAV.
- Table 6 Stability of rAAV at 4 degrees C in unclarified cell lysates.
- Table 7 Effect of benzonase and RQ1 DNase treatment on rAAV vector stability.
- Table 8 AAV purification and concentration.
- nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof, in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated by the usage of the term, the term nucleic acid is often used interchangeably with gene, cDNA, and mRNA encoded by a gene.
- a nucleic acid sequence encoding refers to a nucleic acid which contains sequence information for a structural RNA such as rRNA, a tRNA, or the primary amino acid sequence of a specific protein or peptide, or a binding site for a trans-acting regulatory agent. Unless otherwise indicated, a particular coding nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g. degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated.
- degenerate codon i.e., different codons which encode a single amino acid
- substitutions may be achieved by generating sequences in which the third position of one or more (or all) selected codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al. (1991 ) Nucleic Acid Res. 19:5081 ; Ohtsuka et al. (1985) J. Bio/. Chem. 260:2605-2608; and Cassol et al. (1992); Rossolini et al. (1994) Mol. Cell. Probes 8:91 -98).
- Degenerate codons of the native sequence or sequences which may be introduced to conform with codon preference in a specific host cell.
- sequence in the context of a particular reference nucleic acid refers to a region of the nucleic acid smaller than the reference nucleic acid or poiypeptide.
- Cellular gene means a gene usually expressed by the members of a given cell line or cell type without experimental manipulation. It preferably means an endogenous gene that forms part of the cellular genome. Viral genes that may have been integrated into the cellular genome of an ancestral cell and are presently expressed in all cells of a particular cell line are considered "cellular genes". However, the term specifically excludes genes that are expressed in a particular population of cells due to the deliberate experimental infection of that population with selected viruses.
- a "ribozyme” is a catalytic RNA molecule which cleaves RNA.
- the preferred class of ribozymes for the invention is the hairpin ribozyme; hammerheads are specifically not preferred.
- Preferred hairpin ribozymes cleave target RNA molecules in trans.
- a ribozyme cleaves a target RNA in vitro when it cleaves a target RNA in solution.
- a ribozyme cleaves a target RNA in vivo when the ribozyme cleaves a target RNA in a cell.
- the cell is optionally isolated, or present with other cells, e.g. , as part of a tissue, tissue extract, cell culture, or live organism.
- a ribozyme is active in vivo when it cleaves a target RNA in a cell present in an organism such as a mammal, or when the ribozyme cleaves a target RNA in a cell present in cells or tissues isolated from a mammal, or when it cleaves a target RNA in a cell in a cell culture.
- a ribozyme "recognition sequence” or “helix 1 " ribozyme domain is the portion of a nucleic acid encoding the ribozyme which is complementary to a target RNA 3' of the cleavage site on the target RNA, i.e.
- a GUC ribozyme typically cleaves an RNA having the sequence NNNBCN*GUCNNNNNNNN (SEQ ID NO: 1 ) (where N*G is the cleavage site, B is any of G, U or C, and where N is any of G, U, C, or A).
- GUA ribozymes typically cleave an RNA target sequence consisting of NNNNN*GUANNNNNNNN. (SEQ ID NO:2) (where N*G is the cleavage site and where N is any of G, U, C, or A).
- a “GUA site” is an RNA sub-sequence which includes the nucleic acids GUA which is cleaved b a GUA ribozyme.
- a “GUC site” is an RNA sub-sequence which includes the nucleic acids GUC which is cleaved by a GUC ribozyme.
- a library of hairpin ribozyme-encoding nucleic acids denotes a collection of nucleic acids wherein every possible recognition sequence is represented.
- the nucleotide residue at each position of the recognition sequence other than the GUA or GUC site can be a G, U, C, or A (collectively referred to by an "N", see previous example and Figure 1 ).
- isolated when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state.
- an isolated gene of interest is separated from open reading frames which flank the gene and encode a gene product other than that of the specific gene of interest.
- a "purified” nucleic acid or protein gives rise to essentially one band in an electrophoretic gel, and is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.
- Nucleic acid probes may be DNA or RNA fragments.
- DNA fragments can be prepared, for example, by digesting plasmid DNA, or by use of PCR, or synthesized by either the phosphoramidite method described by Beaucage and Carruthers (1981 ) Tetrahedron Lett. 22: 1859-1862, or by the triester method according to Matteucci et al. (1981 ) J. Am. Chem. Soc, 103:3185, both incorporated herein by reference.
- a double stranded fragment may then be obtained, if desired, by annealing the chemically synthesized single strands together under appropriate conditions or by synthesizing the complementary strand using DNA polymerase with an appropriate primer sequence.
- a specific sequence for a nucleic acid probe is given, it is understood that the complementary strand is also identified and included. The complementary strand will work equally well in situations where the target is a double-stranded nucleic acid.
- nucleic acid probe that hybridizes, duplexes or binds only to a particular target DNA or RNA sequence when the target sequences are present in a preparation of, for example, total cellular DNA or RNA.
- Target nucleic acid sequences refer to those nucleic acid sequences which selectively hybridize to a nucleic acid probe. Proper annealing conditions depend, for example, upon a probe's length, base composition, and the number of mismatches and their position on the probe, and must often be determined empirically. For discussions of nucleic acid probe design and annealing conditions, see, for example, Sambrook et al.
- MOLECULAR CLONING A LABORATORY MANUAL (2d ed.), Vols. 1-3, Cold Spring Harbor Laboratory (hereinafter, Sambrook et al.) or F. Ausubel et al. (ed.) (1987) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing and Wiley-lnterscience, New York (1987).
- a “promoter” is an array of c/s-acting nucleic acid control sequences which direct transcription of an associated nucleic acid.
- a promoter includes nucleic acid sequences near the start site of transcription, such as a polymerase binding site. The promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription.
- a “constitutive” promoter is a promoter which is active under most environmental conditions and states of development or cell differentiation, such as a pol III promoter.
- An “inducible” promoter initiates transcription in response to an extracellular stimulus, such as a particular temperature shift or exposure to a specific chemical..
- a "pol III promoter” is a DNA sequence competent to initiate transcription of associated DNA sequences by pol III. Many such promoters are known, including those which direct expression of known t-RNA genes. A general review of various t-RNA genes can be found in Watson et al. MOLECULAR BIOLOGY OF THE GENE Fourth Edition, The Benjamin Cummings Publishing Co., Menlo Park, CA pages 710-713.
- a nucleic acid of interest is "operably linked" to a promoter, vector or other regulatory sequence when there is a functional linkage in cis between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and the nucleic acid of interest.
- a nucleic acid expression control sequence such as a promoter, or array of transcription factor binding sites
- a promoter that is operably linked to a nucleic acid of interest directs transcription of the nucleic acid.
- a regulatory nucleic acid is one that initiates, causes, enhances or inhibits the expression of a particular selected nucleic acid or gene product, either directly or through its gene product.
- trans-acting regulatory nucleic acids includes nucleic acids that encode initiators, inhibitors and enhancers of transcription, translation, or post-transcriptional (e.g. , RNA splicing factors) or post translational processing factors, kinases, proteases
- an "expression vector” includes a recombinant expression cassette which has a nucleic acid which encodes an RNA that can be transcribed by a cell.
- a “recombinant expression cassette” is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of an encoded nucleic acid in a target cell.
- the expression vector can be part of a plasmid, virus, or nucleic acid fragment.
- the recombinant expression cassette portion of an expression vector includes a nucleic acid to be transcribed, and a promoter.
- the expression cassette also includes, e.g., an origin of replication, and/or chromosome integration elements such as retroviral LTRs, or adeno associated viral (AAV) ITRs.
- exogenous generally denotes a nucleic acid that has been isolated, cloned and Iigated to a nucleic acid with which it is not combined in nature, and/or introduced into and/or expressed in a cell or cellular environment other than the cell or cellular environment in which said nucleic acid or protein may typically be found in nature.
- the term encompasses both nucleic acids originally obtained from a different organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed.
- nucleic acid indicates that the nucleic acid comprises two or more subsequences which are not found in the same relationship to each other in nature.
- the nucleic acid is typically recombinantly produced, having two or more sequences derived from unrelated genes arranged to make a new functional nucleic acid.
- the nucleic acid has a promoter from one gene, such as a human t-RNA gene, arranged to direct the expression of a coding sequence from a different gene, such as an artificial gene coding for a ribozyme.
- heterologous means that the ribozyme is expressed in a cell or location where it is not ordinarily expressed in nature, such as in a T cell which encodes the ribozyme in an expression cassette.
- nucleic acid or protein when used with reference to a nucleic acid or a protein generally denotes that the composition or primary sequence of said nucleic acid or protein has been altered from the naturally occurring sequence using experimental manipulations well known to those skilled in the art. It may also denote that a nucleic acid or protein has been isolated and cloned into a vector or a nucleic acid that has been introduced into or expressed in a cell or cellular environment, particularly in a cell or cellular environment other than the cell or cellular environment in which said nucleic acid or protein may be found in nature.
- Recombinant or “genetically engineered” when used with reference to a cell indicates that the cell replicates or expresses a nucleic acid, or produces a peptide or protein encoded by a nucleic acid, whose origin is exogenous to the cell.
- Recombinant cells can express nucleic acids that are not found within the native (nonrecombinant) form of the cell.
- Recombinant cells can also express nucleic acids found in the native form of the cell wherein the nucleic acids are re-introduced into the cell by artificial means.
- a cell has been "transduced" by an exogenous nucleic acid when such exogenous nucleic acid has been introduced inside the cell membrane.
- Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
- the exogenous DNA may be maintained on an episomal element, such as a plasmid.
- a stably transformed cell is generally one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication, or one which includes stably maintained extrachromosomal plasmids. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter ceils containing the exogenous DNA.
- a vector "transduces” a cell when it transfers nucleic acid into the cell.
- a cell is “stably transduced” by a nucleic acid when a nucleic acid transduced into the cell becomes stably replicated by the cell, either by incorporation of the nucleic acid into the cellular genome, or by episomal replication.
- a vector is "infective" when it transduces a cell, replicates, and (without the benefit of any complementary vector) spreads progeny vector of the same type as the original transducing vector to other cells in an organism or cell culture, wherein the progeny vectors have the same ability to reproduce and spread throughout the organism or cell culture.
- the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample.
- Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein.
- a variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein.
- solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.
- transgene comprises a nucleic acid sequence used to form a chimeric or transgenic animal when introduced into the chromosomal material of the somatic and germ line cells of a non-human animal by way of human intervention, such as by way of the methods described herein to form a transgenic animal.
- the particular embodiments of the transgenes of the invention are described in more detail hereinafter.
- An “embryonic target cell” is a cell into which the transgenes of the invention are introduced to produce "chimeric" animals (wherein only a subset of cells is transduced) or "transgenic" non-human animals (wherein every cell is transduced). Examples include embryonic stem (ES) cells, or preferably the fertilized oocyte (zygote). In some cases, chimeric animals can also be produced by isolating stem cells from an animal, transducing them in vitro, and reinfusing them into the original donor or into an allogeneic recipient.
- ES embryonic stem
- zygote fertilized oocyte
- RNA RNA
- RNA product refers to the RNA produced by transcription or to the polypeptide produced by translation of a nucleic acid.
- Coding a cell denotes that a single cell is proliferated to produce a genetically and phenotypically homogeneous population of progeny cells descended from the single cell .
- Phenotype denotes a definable detectable heritable trait of a cell or organism, that is caused by the presence and action at least one gene.
- a “ligand” is a molecule or chemical compound that detectably and selectively binds to a reference molecule but not to other molecules, preferably with an affinity higher than 10 g M, more preferably greater than 10 "5 M, and most preferably about 10 ⁇ 7 or higher.
- “Sensitivity to a selected chemical compound” means that exposure to a particular chemical compound reproducibly causes a cell to alter its metabolism in predictable ways, e.g. by inducing slower growth, apoptosis, proliferation, induction o or shutdown of certain genes, etc..
- Packaging or “packaged” denotes that a specific nucleic acid or library is contained in and operably linked to a defined vector, such as an adenovirus associated vector. 2. Detailed description of the invention
- a principal objective of this invention is to use a "library" of ribozyme genes containing all possible target recognition sequences to identify, isolate and/or characterize known and unknown genes that encode detectable phenotypic traits. It is also an object to use the library to selectively ablate known and unknown genes, preferably in vivo.
- the most critical considerations are 1 ) the generation of a library with sufficient complexity to assure the presence of ribozymes uniquely specific for any and all given targets, and 2) the competence to package and express, as nearly as possible, the complete library.
- the library must be small enough for it to be technically feasible to make, maintain, and reproducibly manipulate and use.
- a ribozyme library useful for identifying and targeting a gene within the human genome would require a ribozyme library of sufficient complexity to recognize any gene in the genome.
- the target recognition site of the ribozyme should contain at least about 15 to 16 specific nucleotides.
- the hairpin ribozyme is unique in its requirement for a
- Such a hairpin ribozyme library has a complexity of 4 ' ( ⁇ .7 x 10 ) different ribozyme genes or molecules.
- a library of hammerhead ribozymes having a recognition sequence of 15 nucleotides comprises about q 10 different species, which have fewer (if any) stringent sequence requirements in the target (Akhtar et al. (1995) Nature Medicine, 1 :300;
- a hammerhead library involving a 15 nucleotide recognition site would require 64 times more individual ribozyme molecules than a hairpin library involving a recognition sequence of equal size. This is a substantial difference. For this reason, constructing a hairpin ribozyme library, packaging it into a vector, and expressing the entire library in transformed cells is considerably more technically feasible than constructing a similar hammerhead library.
- hairpin ribozymes have over hammerhead ribozymes is their intrinsic stability and folding in vivo.
- the secondary structure of a hammerhead ribozyme, not bound to a target, consists of one helix that is only 4 nucleotides in length which is unlikely to remain intact at physiological temperature, 37° C.
- the crystal structure of the hammerhead could only be solved when it was bound to a DNA or RNA substrate (Pley et al. (1994) Nature 372:68; Scott et al. (1995) Cell 81 :991 ), suggesting that the hammerhead ribozyme does not have a stable structure prior to substrate binding.
- the hairpin ribozyme contains two helices totaling 7 nucleotides ( Figure 1 ), thus making it more stable under physiological temperatures and in the intracellular milieu which contains, among other things, RNases that can more effectively cleave RNAs lacking secondary structure.
- the hairpin ribozyme since the hairpin ribozyme has a more stable secondary structure prior to binding substrate, it would be less likely to improperly fold or interact with flanking sequences in the ribozyme RNA transcript. Sequences comprising a hammerhead riboyzme, however, would be free to interact with any extraneous sequences in the transcript resulting in the inactivation of the ribozyme.
- hairpin ribozymes have over hammerhead ribozymes is that the cleavage success rate of any given target sequence is higher for the hairpin ribozyme than for the hammerhead. This conclusion has been reached empirically, but can also be explained based on the difference between the two ribozymes' target requirements.
- the hammerhead ribozyme is very promiscuous, requiring minimal sequence in the target (see above references). Due to its high promiscuity, it has a relatively low success rate when given a variety of potential sites. Conversely, the hairpin ribozyme has significantly more stringent requirements, where its substrate must contain a GUC.
- hairpin ribozyme library is the generation of target-specific libraries (discussed in detail in section 2.h).
- One method uses the inherent ability of hairpin ribozymes to catalyze a trans-ligation reaction between cleavage products. This ligation capability is significantly more active in the hairpin ribozyme than in the hammerhead (Berzal-Herranz et al (1992) Genes and Development 6: 1 ).
- Construction of a library that encodes hairpin ribozyme genes having randomized recognition sequences typically involves:
- suitable cells e.g. , E. coli
- Synthesis of ribozyme-encoding nucleic acids with randomized sequences may be accomplished by any one of a number of methods known to those skilled in the art. See, e.g. , Oliphant et al. (1986) Gene 44:177-183; U. S. Patents Nos. 5,472,840, and 5,270,163.
- the entire ribozyme-encoding nucleic acid is chemically synthesized by known methods one nucleotide at a time, for example in an ABI 380B synthesizer. Whenever it is desired that a given position be randomized, all four nucleotide monomers are added to the reaction mixture. After synthesis, the end-products are sequenced by any method known in the art to confirm that the catalytic backbone of the hairpin ribozyme is invariant, and that the recognition sequence is randomized.
- a randomized oligonucleotide is spliced to the catalytic region of the hairpin ribozyme. This avoids having to chemically synthesize the entire ribozyme.
- ribozyme genes allow for the constant and continuous production of ribozymes, the ribozyme gene is effectively delivered to the intracellular site of action, and stable gene delivery enables genetic selection of the loss of certain cell functions.
- the randomized library preferably includes at least 10 5 ribozyme o q genes; the upper limit (10 , 10 ⁇ or more) depends on the number of residues in the recognition site.
- the ribozyme library is packaged into a cloning or expression vector by methods known in the art, and the packaged library is cloned into suitable cells and amplified. Although cloning and amplification are typically accomplished using bacterial cells, any combination of cloning vector and cell may be used.
- the cloned cells can be frozen for future amplification and use, or the packaged library can be isolated and itself stored frozen or in lyophilized form.
- Typical cloning vectors contain defined cloning sites, origins of replication and selectable genes.
- Expression vectors typically further include transcription and translation initiation sequences, transcription and translation terminators, and promoters useful for regulation of the expression of the particular nucleic acid.
- Expression vectors optionally comprise generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the cassette in eukaryotes, or prokaryotes, or both, (e.g., shuttle vectors) and selection markers for both prokaryotic and eukaryotic systems.
- the vectors contain a nuclear processing signal, appropriate spicing signals and RNA stability sequences and/or structures (e.g. stable stem-loops, etc.) at either 5' or 3' or both ends, all of which will be present in the expressed ribozyme RNA transcript.
- Vectors are suitable for replication and integration in prokaryotes, eukaryotes, or preferably both.
- cloning, packaging, and expression systems and methods see Giliman and Smith (1979) Gene 8:81-97; Roberts et al. (1987) Nature 328:731 -734; Berger and Kimmel (1989) GUIDE TO MOLECULAR CLONING TECHNIQUES, METHODS IN ENZYMOLOGY, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook et al. (1989) MOLECULAR CLONING - A LABORATORY MANUAL (2nd ed.) Vols.
- the nucleic acids used in the present method can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic methods. Synthetic nucleic acids can be prepared by a variety of solution or solid phase methods. Detailed descriptions of the procedures for solid phase synthesis of nucleic acids by phosphite-triester, phosphotriester, and H-phosphonate chemistries are widely available. See, for example, Itakura, U.S. Pat. No. 4,401 ,796; Caruthers, et al., U.S. Pat. Nos. 4,458,066 and 4,500,707; Beaucage, et al.
- the ribozyme library is expressed in a variety of recombinantly engineered cells and organisms.
- compositions and methods of the present invention are used to transfer nucleic acids, particularly ribozyme-encoding nucleic acids, into a wide variety of cell types, in vivo and in vitro.
- the delivery of nucleic acids can be to any cell that can be grown or maintained in culture, whether of bacterial, plant or animal origin, vertebrate or invertebrate, and of any tissue or type.
- the preferred cell will be one in which the target gene is normally expressed (i.e. liver cells for liver-specific genes, tumor cells for oncogenes, etc.) or has been caused to be expressed.
- the cell would preferably contain a reporter or sortable gene to expedite the selection process.
- nucleic acids there are several well-known methods of introducing nucleic acids into bacterial, animal or plant cells, any of which may be used in the present invention. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the nucleic acid, treatment of the recipient cells with liposomes containing the nucleic acid, DEAE dextran, receptor-mediated endocytosis, electroporation, micro-injection of the nucleic acid directly into the cells, infection with viral vectors, etc. Cationic liposomes-mediated delivery of AAV-ribozyme-library pro-vector plasmid may be employed (Philp et al. (1994) Mol. Cell. Biol. 14:241 1 -2418).
- the concentration of nucleic acid varies widely depending on the particular application, but is generally between about 1 micromolar and about 10 millimolar.
- Treatment of the cells with the nucleic acid is generally carried out at physiological temperatures (37° C) for periods of time of from about 1 to 48 hours, preferably of from 4 to 12 hours.
- cells are incubated with vector at an appropriate multiplicity of infection (m.o.i.Mdepends on application, see below) for 4 to 16 hours (Flotte et al. (1994) Am. J. Resp. Cell Mol. Biol. 1 1 :517).
- a nucleic acid is added to 60-80% confluent plated cells having a cell density of from about 10 3 to about 10 5 cells/mL, more preferably about 2 x 10 4 cells/mL.
- the concentration of the suspension added to the cells is preferably of from about 0.01 to 0.2 micrograms/mL, more preferably about 0.1 micrograms/mL.
- a reporter gene is one whose gene product is readily inducible and/or detectable, that is used to detect cells that are transduced with a vector that encodes the reporter gene, to isolate and clone such cells, and to monitor the effects of environmental and cytoplasmic factors on gene expression in the transduced cells.
- Preferred reporter genes are those that render cells FACS-sortable: e.g., genes for fluorescent proteins, including green fluorescent protein (GFP) and any mutant thereof; nerve growth factor receptor (NGFR) and any mutant thereof; genes for cell surface proteins that may be coupled to easily detected ligands such as fluorescent antibodies.
- reporter genes that can be selected for or against in tissue culture, which may be used herein include the hprt gene (Littlefield (1964) Science 145:709-710), the tk (thymidine kinase) gene of herpes simplex virus (Giphart-Gassler et al. (1989) Mutat. Res. 214:223-232), the nDtll gene (Thomas et al. (1987) Cell 51 :503-512; Mansour et al. (1988) Nature 336:348-352), or other genes which confer resistance or sensitivity to amino acid or nucleoside analogues, or antibiotics, etc.
- hprt gene Littlefield (1964) Science 145:709-710
- tk thymidine kinase gene of herpes simplex virus
- nDtll gene Thimas et al. (1987) Cell 51 :503-512
- reporter genes are used herein to identify cells that have been transduced with nucleic acids that encode a ribozyme and or a gene of interest. It is possible that a given cell clone identified as under-expressing the reporter gene may contain a ribozyme gene that cleaves the gene product of the reporter gene instead of the gene of interest, in which case the ribozyme genes against the reporter gene will be mis-identified as ribozymes directed against the gene of interest. Thus, it is preferable to generate a cell line that co-expresses at least two or three different reporter genes linked to the gene of interest. Only ribozyme genes that inhibit the gene of interest will result in under-expression of more than one reporter gene simultaneously.
- a number of viral vector systems can be used to express ribozyme libraries in vivo, including retroviral vectors, vaccinia vectors, herpes simplex vectors, Sindbis/semliki forest viruses, adenoviral vectors, and adeno-associated viral (AAV) vectors.
- retroviral vectors vaccinia vectors
- herpes simplex vectors herpes simplex vectors
- Sindbis/semliki forest viruses adenoviral vectors
- adenoviral vectors adeno-associated viral (AAV) vectors.
- AAV adeno-associated viral
- Optimal delivery systems are characterized by: 1 ) broad host range; 2) high titer/ ⁇ g DNA; 3) stable expression; 4) non-toxic to host cells; 5) no replication in host cells; 6) ideally no viral gene expression; 7) stable transmission to daughter cells; 8) high rescue yield; and 9) lack of subsequent replication-competent virus that may interfere with subsequent analysis.
- Choice of vector may depend on the intended application.
- adeno-associated viral vector are preferred to deliver ribozyme library genes into target cells. See, e.g., D.V. Goeddel (ed.) (1990) Methods in Enzymology, Vol. 185, Academic Press, Inc., San Diego, CA or M. Krieger (1990) GENE TRANSFER AND EXPRESSION -- A LABORATORY MANUAL, Stockton Press, New York, NY, and the references cited therein.
- AAV requires helper viruses such as adenovirus or herpes virus to achieve productive infection.
- AAV displays a very broad range of hosts including chicken, rodent, monkey and human cells
- rodent, monkey and human cells Mazycka, N., 1992 Curr. Top. Microbiol. Immunol. 158, 97-129; Tratschin et al., 1985, Mol. Cell. Biol. 5:3251 -3260; Lebkowski er a/., 1988. Mol. Cell. Biol. 8:3988-3996.
- They efficiently transduce a wide variety of dividing and non-dividing cell types in vitro (Flotte, T.R, et al., 1992. Am. J. Respir. Cell. Mol. Biol. 7, 349-356; Podsakoff, G. et al. 1994. J. Virol.
- AAV vectors have been demonstrated to successfully transduce hematopoietic progenitor cells of rodent or human origin (Nahreini, Py et al., 1991 , Blood, 78:2079). It is believed that AAV could virtually infect any mammalian cell type.
- the copy number for the neo gene introduced by the AAV vector is more than 2 orders of magnitude higher than that of retrovirally- transduced human tumor-infiltrating lymphocyte (TIL) cell cultures.
- TIL tumor-infiltrating lymphocyte
- the integrated AAV genome has no pathogenic effect.
- the integration step allows the AAV genome to remain genetically intact until the host is exposed to the appropriate environmental conditions (e.g. , a lytic helper virus), whereupon it re-enters the lytic life-cycle.
- the entire AAV-ribozyme expression cassette can be easily "rescued” from the host cell genome and amplified by introduction of the AAV viral proteins and wild type adenovirus (Hermonat P.L. and N. Muzyczka (1984) PNAS. USA 81 :6466-6470; Tratschin, J. et al. (1 985) Mol. Cell. Biol. 5:3251 -3260; Samulski, R.J. et al (1982) PNAS USA 79:2077-2081 ; Tratschin et al. (1985) Mol. Cell. Biol. 5:3251 -3260).
- the complexity of the ribozyme library is monitored as follows:
- Cells expressing an HSV-tk gene or transduced with an pHSV-TK gene are transduced with either an AAV vector or an AAV-ribozyme-Lib vector, and cultured in the presence of gancyclovir and G41 8.
- Cells that lack a functional ribozyme that cleaves the tk mRNA will express thymidine kinase and die. Ceils that inactivate the HSV tk gene product with one or more specific ribozymes will survive.
- Surviving cells are amplified, and the sequence of the anti-HSV tk ribozyme is determined by PCR of ribozyme gene(s), followed by sequencing analysis of the amplified product.
- the ribozyme gene sequences that are complementary to regions of the tk gene sequence can be used as a gene probe for HSV tk gene. Once ribozymes that appear to inactive tk have been isolated, their catalytic activity can be verified by converting them into "disabled” ribozymes (i.e. disrupting their catalytic activity without affecting substrate binding, see section 2.h. How to distinguish between ribozyme effects... above for a more detailed description) followed by re-analyzing their effects in vivo. Alternatively, cells expressing any other selectable or FACS-sortable marker, such as green fluorescent protein (GFP) or Erb, can also be used as the target for testing the complexity of the invented AAV-ribozyme library vector.
- GFP green fluorescent protein
- Erb Erb
- Retroviral vectors may also be used in certain applications.
- the design of retroviral vectors is well known to one of skill in the art. See Singer, M. and Berg, P., supra.
- the sequences necessary for encapsidation or packaging of retroviral RNA into infectious virions
- the result is a cis acting defect which prevents encapsidation of genomic RNA.
- the resulting mutant is still capable of directing the synthesis of all virion proteins.
- Retroviral genomes from which these sequences have been deleted, as well as cell lines containing the mutant genome stably integrated into the chromosome are well known in the art and are used to construct retroviral vectors.
- the retroviral vector particles are prepared by recombinantly inserting a nucleic acid encoding a nucleic acid of interest into a retrovirus vector and packaging the vector with retroviral capsid proteins by use of a packaging cell line.
- the resultant retroviral vector particle is generally incapable of replication in the host cell and is capable of integrating into the host cell genome as a provirai sequence containing the calbindin nucleic acid.
- the host cell produces the gene product encoded by the nucleic acid of interest.
- Packaging cell lines are generally used to prepare the retroviral vector particles.
- a packaging cell line is a genetically constructed mammalian tissue culture cell line that produces the necessary viral structural proteins required for packaging, but which is incapable of producing infectious virions.
- Retroviral vectors lack the structural genes but have the nucleic acid sequences necessary for packaging.
- a packaging cell line an infectious clone of a desired retrovirus, in which the packaging site has been deleted, is constructed. Cells comprising this construct will express all structural proteins but the introduced DNA will be incapable of being packaged.
- packaging cell lines can be produced by transducing a cell line with one or more expression plasmids encoding the appropriate core and envelope proteins. In these cells, the gag, pol, and env genes can be derived from the same or different retroviruses.
- a number of packaging cell lines suitable for the present invention are available in the prior art. Examples of these cell lines include Crip, GPE86, PA317 and PG13. See Miller et al. (1991 ) J. Virol. 65:2220-2224, which is incorporated herein by reference. Examples of other packaging cell lines are described in Cone, R. and Mulligan, R.C. (1984) Proceedings of the National Academy of Sciences, U.S.A. 81 :6349-6353 and in Danos, O. and R.C. Mulligan (1988) Proceedings of the National Academy of Sciences, U.S.A. 85:6460-6464; Eglitis et al. (1988) Biotechniques 6:608-614; Miller, A.D. et al.
- Amphotropic or xenotropic envelope proteins such as those produced by PA317 and GPX packaging cell lines may also be used to package the retroviral vectors.
- RVV retroviral vectors
- Sindbis/semliki forest viruses (Berglund et al. (1993) Biotechnology 1 1 :91 6-920) are positive-strand RNA viruses that replicate in the cytoplasm, are stably maintained, and can yield very high levels of antisense RNA. Sindbis vectors are thus a third type of vector useful for maximal utility.
- the promoters used to control the gene expression from AAV include: (a) viral promoters such as SV40, CMV, retroviral LTRs, herpes virus TK promoter, parvovirus B-19 promoter (Muzycka, N, 1992, Curr. Top. Microbiol. Immunol. 1 58, 97-1 29), AAV p5 and p40 promoters (Tratschin, J.D., et al., 1993. Am. J. Respir. Cell. Mol. Biol. 7, 349-356). (b) human gene promoters such as the gamma-globin promoter (Walsh, C.F. et al., 1992, Proc. Nat. Acad. Sci.
- viral promoters such as SV40, CMV, retroviral LTRs, herpes virus TK promoter, parvovirus B-19 promoter (Muzycka, N, 1992, Curr. Top. Microbiol. Immunol. 1 58, 97-1
- RNA pol III promoters such as cellular tRNA promoters or the promoter from the adenovirus VA1 gene (U.S. application serial No. 08/664,094; U.S. application serial No. 08/719,953)
- a number of embodiments of the present invention require detecting and quantifying specific nucleic acids, such as specific genes, RNA transcripts or ribozymes.
- specific nucleic acids such as specific genes, RNA transcripts or ribozymes.
- a variety of methods for specific DNA and RNA detection and measurement, many involving nucleic acid hybridization techniques, are known to those of skill in the art. See Sambrook, et al.; Hames and Higgins (eds.) (1985) NUCLEIC ACID HYBRIDIZATION, A PRACTICAL APPROACH, IRL Press; Gall and Pardue (1969) Proc. Natl. Acad. Sci. USA, 63:378-383; and John et al. (1969) Nature 223:582-587.
- the selection of a particular hybridization format is generally not critical.
- Hybridization is carried out using nucleic acid probes which are designed to be complementary to the nucleic acid sequences to be detected.
- the probes can be full length or less than the full length of the target nucleic acid.
- nucleic acid probes are 20 bases or longer in length. Shorter probes are empirically tested for specificity. (See Sambrook, et al. for methods of selecting nucleic acid probe sequences for use in nucleic acid hybridization.)
- desired nucleic acids will hybridize to complementary nucleic acid probes under the hybridization and wash conditions of 50% formamide at 42° C.
- Other stringent hybridization conditions may also be selected.
- stringent conditions are selected to be about 5° C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.
- the Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.
- stringent conditions will be those in which the salt concentration is at least about 0.02 molar at pH 7 and the temperature is at least about 60° C.
- the combination of parameters is more important than the absolute measure of any one.
- Oligonucleotides for use as probes are chemically synthesized, for example, according to the solid phase phosphoramidite triester method first described by Beaucage, S.L. and Carruthers, M.H., 1981 , Tetrahedron Lett. , 22(20): 1859-1862 using an automated synthesizer, as described in Needham-VanDevanter, D.R., et al., 1984, Nucleic Acids Res. , 12:61 59-61 68. Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson, J.D. and Regnier, F.E. (1983) J. Chrom. 255: 137-149. The sequence of the synthetic oligonucleotide can be verified using the chemical degradation method of Maxam, A.M. and Gilbert, W. (1980) in Methods Enzymol. 65:499-560.
- the probes used to detect hybridization are labeled to facilitate detection.
- Complementary nucleic acids or signal nucleic acids may be labeled by any one of several methods typically used to detect the presence of hybridized polynucleotides. The most common method of detection is the use of autoradiography with 3 H, 1 25 l, 35 S, 14 C, or 32 P-labeled probes or the like.
- Other labels include iigands which bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand.
- RNA molecules may be used for the detection of particular RNA molecules.
- total RNA is isolated from a given cell sample using an acid guanidinium-phenol-chloroform extraction method. The RNA is then electrophoresed to separate the RNA species and the RNA is transferred from the gel to a nitrocellulose membrane. As with the Southern blots, labeled probes are used to identify the presence or absence of particular RNAs.
- in situ hybridization assays are well known and are generally described in Angerer, et al. (1987) Methods Enzymol. 152:649-660.
- in situ hybridization assay cells are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of labeled probes specific to the targeted nucleic acids.
- the probes are preferably labeled with radioisotopes or fluorescent reporters.
- the sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system which multiplies the target nucleic acid being detected, in vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known.
- in vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known.
- examples of techniques sufficient to direct persons of skill through such in vitro amplification methods including the polymerase chain reaction (PCR) the ligase chain reaction (LCR), Q_-replicase amplification and other RNA polymerase mediated techniques (e.g. , NASBA) are found in Berger, Sambrook, and Ausubel, as well as Mullis et al. (1 987) U.S. Patent No.
- a preferred method of amplifying target sequences is the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- oligonucleotide primers complementary to the two 3' borders of the nucleic acid region to be amplified are synthesized.
- the polymerase chain reaction is then carried out using the two primers. See Innis, M., Gelfand, D., Sninsky, J. and White, T. (eds.) (1990) PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS Academic Press, San Diego.
- Primers can be selected to amplify the entire regions encoding a full-length ribozyme or selected subsequence, or to amplify smaller nucleic acid segments as desired.
- Gene products such as polypeptides may be detected or quantified by a variety of methods. Preferred methods involve the use of specific antibodies.
- an immunogen polypeptide or a fragment thereof is isolated or obtained as described herein.
- Mice or rabbits, typically from an inbred strain, are immunized with the immunogen protein using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol.
- a synthetic peptide derived from proteins disclosed herein and conjugated to a carrier protein can be used as an immunogen.
- Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support.
- Polyclonal antisera with a titer of 10 4 or greater are selected and tested for their cross reactivity against protein related or unrelated to the immunogen, using a competitive binding immunoassay.
- Specific monoclonal and polyclonal antibodies and antisera will usually bind to the immunogen with a K D of at least about .1 mM, more usually at least about 1 micromolar, preferably at least about .1 micromolar or better, and most preferably .01 micromolar or better.
- a number of immunogens may be used to produce antibodies specifically reactive with a particular peptide antigen.
- Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies.
- Naturally occurring protein may also be used either in pure or impure form.
- Synthetic peptides made using the sequences described herein may also used as an immunogen for the production of antibodies to the protein.
- Recombinant protein can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein. Methods of production of polyclonal antibodies are known to those of skill in the art.
- an immunogen preferably a purified protein
- an adjuvant preferably a human milk
- animals are immunized.
- the animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the immunogen.
- blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired. (See Harlow and Lane, supra).
- Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (See, Kohler and Milstein (1976) Eur. J. Immunol. 6:51 1 -519 incorporated herein by reference). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art.
- Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host.
- a particular protein can be measured by a variety of immunoassay methods.
- immunoassay methods for a review of immunological and immunoassay procedures in general, see BASIC AND CLINICAL IMMUNOLOGY 7th Edition (D. Stites and A. Terr ed.) 1991 .
- the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in Maggio, E.T. (ed.) (1980) Enzyme Immunoassay, CRC Press, Boca Raton, Florida; Tijssen, P. (1985) "Practice and Theory of Enzyme Immunoassays" in LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, Elsevier Science Publishers B.V.
- Immunoassays to peptides of the present invention may use a polyclonal antiserum which was raised to a defined protein, or a fragment thereof. This antiserum is selected to have low crossreactivity against other proteins and any such crossreactivity (for example, cross-reactivity against equivalent proteins from different species or tissues) is removed by immunoabsorbtion prior to use in the immunoassay.
- the antigen protein, or a fragment thereof is isolated as described herein.
- recombinant protein is produced in a transformed cell line.
- An inbred strain of mice such as balb/c is immunized with the selected protein of using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol.
- a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used an immunogen.
- Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support.
- Polyclonal antisera with a titer of 10 or greater are selected and tested for their cross reactivity against proteins other than the antigen, using a competitive binding immunoassay such as the one described in Harlow and Lane, supra, at pages 570-573.
- Immunoassays in the competitive binding format can be used for the crossreactivity determinations.
- the selected protein can be immobilized to a solid support.
- Proteins either distinct from, or related to, the antigenic protein
- the ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the antigenic protein.
- the percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with the antigenic proteins are selected and pooled.
- the cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorbtion with the above-listed proteins.
- the immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein to the immunogen protein.
- the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than 10 times the amount of the immunogen protein that is required, then the second protein is said to specifically bind to an antibody generated to the immunogen protein.
- the presence of a desired polypeptide (including peptide, transcript, or enzymatic digestion product) in a sample may be detected and quantified using Western blot analysis.
- the technique generally comprises separating sample products by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with labeling antibodies that specifically bind to the analyte protein.
- the labeling antibodies specifically bind to protein on the solid support.
- labeling agents such as antibodies (e.g. , labeled sheep anti-mouse antibodies where the antibody to a protein is a murine antibody) that specifically bind to the labeling antibody.
- nucleic acid sequences which encode ribozymes or other desired gene products. See Sambrook et al.
- DNA is isolated from a genomic or cDNA library by hybridization to immobilized oligonucleotide probes complementary to the desired sequences.
- probes designed for use in amplification techniques such as PCR are used, and the desired nucleic acids may be isolated using methods such as PCR.
- nucleic acids having a defined sequence may be chemically synthesized in vitro.
- mixtures of nucleic acids may be electrophoresed on agarose gels, and individual bands excised.
- Recombinant phage are analyzed by plaque hybridization as described in Benton and Davis (1977) Science 196: 180-1 82. Colony hybridization is carried out as generally described in M. Grunstein et al. (1975) Proc. Natl. Acad. Sci. USA., 72:3961 -3965.
- a cDNA library is generated by reverse transcription of total cellular mRNA, followed by in vitro packaging and transduction into a recombinant host.
- DNA encoding a particular gene product is identified in either cDNA or genomic libraries by its ability to hybridize with nucleic acid probes, for example on Southern blots, and these DNA regions are isolated by standard methods familiar to those of skill in the art. See Sambrook et al.
- a desired nucleic acid is detected in a mixture of nucleic acids, it is Iigated into an appropriate vector and introduced into an appropriate cell, and cell clones that contain only a particular nucleic acid are produced.
- strains of bacterial cells such as E. co/i are used for cloning, because of the ease of maintaining and selecting bacterial cells.
- PCR can be also used in a variety of protocols to isolate nucleic acids.
- appropriate primers and probes for amplifying a nucleic acid encoding a particular sequence are generated from analysis of the nucleic acid sequences listed herein. Once such regions are PCR-amplified, they can be sequenced and oligonucleotide probes can be prepared from the sequence obtained. These probes can then be used to isolate nucleic acid's encoding the sequence.
- nucleic acid sequence based amplification NASBATM, Cangene, Mississauga, Ontario
- Q Beta Replicase systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or Iigated only when a select sequence is present.
- the select sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.
- polypeptides of this invention may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, for instance, R. Scopes (1982) PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Springer-Verlag: New York, incorporated herein by reference.
- the proteins and polypeptides produced by recombinant DNA technology may be purified by a combination of cell lysis (e.g., sonication) and affinity chromatography or immunoprecipitation with a specific antibody to the target protein.
- cell lysis e.g., sonication
- affinity chromatography e.g., affinity chromatography
- immunoprecipitation e.g., antigene
- the proteins may then be further purified by standard protein chemistry techniques.
- the ribozymes in the ribozyme library can be expressed in a chimeric animal or in a non-human transgenic animal.
- the transgenic animals of the invention comprise any non-human animal or mammal, such as non-human primates, ovine, canine, bovine, rat and murine species as well as rabbit and the like.
- Preferred non-human animals are selected from the rodent family, including rat, guinea pig and mouse, most preferably mouse.
- a female non-human animal is induced to superovulate by the administration of hormones such as follicle-stimulating hormone, the eggs are either collected and fertilized in vitro or the superovulated female is mated to a male and the zygotes are collected, and the zygote is transduced with one or more selected vectors comprising a ribozyme library and/or a preselected nucleic acid.
- hormones such as follicle-stimulating hormone
- the eggs are either collected and fertilized in vitro or the superovulated female is mated to a male and the zygotes are collected, and the zygote is transduced with one or more selected vectors comprising a ribozyme library and/or a preselected nucleic acid.
- the preferred method of transgene introduction is by microinjection.
- other methods such as retroviral or adenoviral infection, electroporation, or liposomal fusion can be used.
- transgenic non-human animals Specific methods for making transgenic non-human animals are described in the following references: Pinkert CA. (ed.) (1994) TRANSGENIC ANIMAL TECHNOLOGY: A LABORATORY HANDBOOK Academic Press and references cited therein; Pursel et al. (1989) Genetic engineering of livestock, Science 244: 1281 -1288, especially p. 1282-1283, Table 1 at p. 1283; Elbrecht A. et al. (1987) "Episomal Maintenance of a Bovine Papilloma Virus Vector in Transgenic Mice," Mol. Cell. Biol. 7(3):1276-1279; Hammer et al.
- the male pronucleus reaches the size of approximately 20 micrometers in diameter which allows reproducible injection of 1 -2 pi of DNA solution.
- the use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host gene before the first cleavage (Brinster, et al. (1985) Proc. Natl. Acad. Sci. USA 82:4438-4442).
- all cells of the transgenic non-human animal will carry the incorporated transgene. This will, in general, also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene.
- the cell is implanted into the uterus of a receptive female (i.e. , a female whose uterus is primed for implantation, either naturally or by the administration of hormones), and allowed to develop into an animal. Since all of the animal's cells are derived from the implanted fertilized egg, all of the ceils of the resulting animal (including the germ line cells) shall contain the introduced gene sequence. If, as occurs in about 30% of events, the first cellular division occurs before the introduced gene sequence has integrated into the cell's genome, the resulting animal will be a chimeric animal.
- transgenic animals By breeding and inbreeding such animals, it has been possible to produce heterozygous and homozygous transgenic animals. Despite any unpredictability in the formation of such transgenic animals, the animals have generally been found to be stable, and to be capable of producing offspring which retain and express the introduced gene sequence. The success rate for producing transgenic animals is greatest in mice. Approximately 25% of fertilized mouse eggs into which DNA has been injected, and which have been implanted in a female, will become transgenic mice.
- AAV or retroviral infection can also be used to introduce a transgene into an animal.
- AAV are preferred because high m.o.i. infections can result in multiple copies stably integrated per cell.
- Multiple copies of transgene are beneficial because: (a) increased level of transgene expression, (b) it reduces the chance that the target cell will lose or "kick out" the transgene, (c) transgene expression is not completely lost if one copy is mutated or inactivated and (d) it increases the likelihood of transgene expression in all lineages when the original target cell undergo any differentiation.
- the developing non-human embryo can be cultured in vitro to the blastocyst stage.
- the blastomeres can be targets for retroviral infection (Jaenich (1976) Proc. Natl. Acad. Sci USA 73: 1260-1264). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan, et al. (1986) in MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
- the viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner et al. (1985) Proc. Natl. Acad. Sci. USA 82:6927-6931 ; Van der Putten et al.
- the founder may contain various retroviral insertions of the transgene at different positions in the genome which generally will segregate in the offspring, in addition, it is also possible to introduce transgenes into the germ line, albeit with low efficiency, by intrauterine retroviral infection of the mid-gestation embryo (Jahner et al. (1982) supra).
- a third and preferred target cell for transgene introduction is the embryonic stem cell (ES).
- ES cells are obtained from pre-implantation embryos cultured in vitro and fused with embryos (Evans et al. (1981 ) Nature 292: 1 54-1 56; Bradley et al. (1984) Nature 309:255-258; Gossler et al. (1986) Proc. Natl. Acad. Sci USA 83:9065-9069; and Robertson et al. (1986) Nature 322:445-448).
- Transgenes can be efficiently introduced into the ES cells a number of means well known to those of skill in the art.
- Such transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal (for a review see Jaenisch (1988) Science 240: 1468-1474).
- the DNA molecule containing the desired gene sequence may be introduced into the pluripotent cell by any method which will permit the introduced molecule to undergo recombination at its regions of homology.
- Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction.
- any gene sequence whose presence in a cell permits one to recognize and clonally isolate the cell may be employed as a detectable (selectable) marker gene sequence.
- the presence of the detectable (selectable) marker sequence in a recipient cell is recognized by hybridization, by detection of radiolabelled nucleotides, or by other assays of detection which do not require the expression of the detectable marker sequence.
- such sequences are detected using polymerase chain reaction (PCR) or other DNA amplification techniques to specifically amplify the DNA marker sequence (Mullis et al. (1986) Cold Spring Harbor Symp. Quant. Biol. 51 :263-273; Erlich et al. EP 50,424; EP 84,796, EP 258,017 and EP 237,362; Mullis EP 201 , 184; Mullis et al., U.S. Patent No. 4,683,202; Erlich U.S. Patent No. 4,582,788; and Saiki et al. U.S. Patent No. 4,683, 194).
- PCR polymerase chain reaction
- the detectable marker gene sequence will be expressed in the recipient cell, and will result in a selectable or at least a detectable phenotype.
- Selectable markers are well known to those of skill in the art. Some examples include the hprt gene (Littlefield (1964) Science 145:709-710), the tk (thymidine kinase) gene of herpes simplex virus (Giphart-Gassler et al. (1989) Mutat, Res. 214:223-232), the nDtll gene (Thomas et al. (1987) Cell 51 :503-512; Mansour et al. (1 988) Nature 336:348-352), or other genes which confer resistance to amino acid or nucleoside analogues, or antibiotics, etc.
- embryonic cells which express an active HPRT enzyme are unable to grow in the presence of certain nucleoside analogues (such as 6-thioguanine, 8-azapurine, etc.), but are able to grow in media supplemented with HAT (hypoxanthine, aminopterin, and thymidine).
- HAT hypoxanthine, aminopterin, and thymidine
- cells which fail to express an active HPRT enzyme are unable to grow in media containing HATG, but are resistant to analogues such as 6-thioguanine, etc. (Littlefield (1964) Science 145:709-710).
- HSV-tk Cells expressing active thymidine kinase are able to grow in media containing HAT, but are unable to grow in media containing nucleoside analogues such as bromo-deoxyuridine (Giphart-Gassler et al. (1989) Mutat. Res. 214:223-232). Cells containing an active HSV-tk gene are incapable of growing in the presence of gangcylovir or similar agents. This strategy can be useful following gene delivery to either ES cells or unfertilized eggs.
- the HSV-tk approach is especially suited to ES/blastocyst delivery or selelction of developing zygotes since the "bystander effect" of tk (Freeman et al.
- the detectable marker gene may also be any gene which can compensate for a recognizable cellular deficiency.
- the gene for HPRT could be used as the detectable marker gene sequence when employing cells lacking HPRT activity.
- this agent is an example of agents may be used to select mutant cells, or to "negatively select" for cells which have regained normal function.
- Chimeric or transgenic animal cells of the present invention are prepared by introducing one or more DNA molecules into a precursor pluripotent cell, most preferably an ES cell, or equivalent (Robertson in Capecchi, M.R. (ed.) (1989) CURRENT COMMUNICATIONS IN MOLECULAR BIOLOGY, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., pp. 39-44).
- a precursor pluripotent cell most preferably an ES cell, or equivalent
- the term "precursor” is intended to denote only that the pluripotent cell is a precursor to the desired (“transfected") pluripotent cell which is prepared in accordance with the teachings of the present invention.
- the pluripotent (precursor or transfected) cell may be cultured in vivo, in a manner known in the art (Evans et al. (1981 ) Nature 292: 154-156) to form a chimeric or transgenic animal.
- the transfected cell, and the cells of the embryo that it forms upon introduction into the uterus of a female are herein referred to respectively, as "embryonic stage" ancestors of the cells and animals of the present invention.
- Any ES cell may be used in accordance with the present invention. It is, however, preferred to use primary isolates of ES cells. Such isolates may be obtained directly from embryos such as the CCE cell line disclosed by Robertson, E.J., In Capecchi, M.R. (ed.) (1989) CURRENT COMMUNICATIONS IN MOLECULAR BIOLOGY, Cold Spring Harbor Press, Cold Spring Harbor, NY, pp. 39-44), or from the clonal isolation of ES cells from the CCE cell line (Schwartzberg et al. (1989) Science 212:799-803). Such clonal isolation may be accomplished according to the method of Robertson in Robertson, E.J.
- ES cell lines which have been clonally derived from embryos are the ES cell lines, AB1 (hprt + ) or AB2.1 (hprf).
- this invention utilizes Ola-derived E14 ES cells.
- the E14 embryonic stem cells are in the American Type Tissue Culture Repository at 12301 Parklawn Dr., Rockville, Maryland USA, under accession number CRL1821.
- the ES cells are preferably cultured on stromal cells (such as STO cells (especially SNL76/7 STO cells) and/or primary embryonic G418 R fibroblast cells) as described by Robertson, supra.
- stromal cells such as STO cells (especially SNL76/7 STO cells) and/or primary embryonic G418 R fibroblast cells
- Methods for the production and analysis of chimeric mice are well known to those of skill in the art (see, for example, Bradley in Robertson, E.J. (ed.) (1987) TERATOCARCINOMAS AND EMBRYONIC STEM CELLS; A PRACTICAL APPROACH, IRL Press, Oxford, pp. 1 13- 151 ).
- the stromal (and/or fibroblast) cells serve to eliminate the clonal overgrowth of abnormal ES cells.
- the cells are cultured in the presence of leukocyte inhibitory factor (“lif”) (Gough et al. (1989) Reprod. Fertil. 1 :281-288; Yamamori et al. (1989) Science 246: 1412-1416).
- lif leukocyte inhibitory factor
- ES cell lines may be derived or isolated from any species (for example, chicken, etc.) , although cells derived or isolated from mammals such as rodents, rabbits, sheep, goats, fish, pigs, cattle, primates and humans are preferred. Cells derived from rodents (i.e. mouse, rat, hamster etc.) are particularly preferred.
- rodents i.e. mouse, rat, hamster etc.
- ribozymes Distinguishing between true catalytic activity and antisense activity is critical for the selection of active ribozymes. Assays in cell culture allow selection of specific ribozymes out of the AAV-delivered ribozyme library. Ribozymes initially selected inactivate expression of the target through either truly catalytic or simply antisense mechanisms. Less likely, although possible, the integration of the AAV genome could disrupt gene function as well.
- the AAV-ribozyme genome is "rescued" from the host cell genome by transfection with a plasmid expressing the AAV viral proteins along with infection with wild type adenovirus.
- the AAV produced from these transfected/infected cells rescue and package the original AAV-ribozyme genome into new AAV particles. These are then used to infect fresh cells and assayed for loss of gene function. Ribozyme-dependent activity would continue to knock out the specific gene.
- the selected ribozyme gene is structurally modified to abolish the cleavage activity without affecting substrate binding. This is also important so that a unique probe to the gene, including the GUC, can be generated.
- a three base mutation of AAA to CGU in loop 2 of the hairpin ribozyme ( Figure 1 ) has been identified that disables the ribozyme cleavage activity without disrupting its substrate binding (Anderson et al. (1994) Nucleic Acids Res. 22: 1096; Ojwang et al. (1992) Proc. Natl. Acad. Sci. USA 89: 10802).
- This mutation is then introduced into the selected ribozymes by PCR amplification using the 3' disabled primer that contains the mutation.
- This new pool of "disabled” selected ribozymes is then re-introduced into AAV and assayed again for activity in cell culture. All AAV-disabled ribozyme clones that retain the ability to inactivate gene expression function through an antisense mechanism, while AAV-disabled ribozyme clones that lose this ability are indicative of an activity dependent on the ribozymes catalytic activity.
- Hairpin ribozyme libraries with randomized ribozyme recognition sites are used in a variety of Ribozyme-Mediated Gene Functional Analyses (RiMGFA), in which comparison of biological properties of cells with or without gene-inactivating ribozymes reveals the function and/or identity of a given gene.
- RiMGFA Ribozyme-Mediated Gene Functional Analyses
- the methods described herein are used to detect and then isolate unknown genes that result in a measurable phenotypic traits.
- a ribozyme that is shown to result in a given phenotype is isolated and sequenced.
- the ribozyme recognition sequence is used to detect, isolate and characterize genes that contain sequences complementary to the recognition sequence.
- the methods of the invention are used to detect genes that mediate sensitivity and resistance to a selected defined chemical substance; examples include: drug toxicity genes; genes that encode resistance or sensitivity to carcinogenic chemicals; genes that encode resistance or sensitivity to infections with specific viral and bacterial pathogens.
- the methods of the invention are also used to detect unknown genes that mediate binding to a ligand, such as hormone receptors, viral receptors, and cell surface markers.
- the methods of the invention are also used to detect unknown tumor suppressor, transformation, and differentiation genes.
- RNA targets viral RNA, cellular mRNA, etc.
- RFLPs restriction fragment length polymorphisms
- ribozyme cleavage sites have been deduced by brute force, synthesizing individual ribozymes one at a time and assaying their activity on a large target RNA in vitro. Furthermore, in many instances, ribozymes that cleave in vitro do not cleave in vivo (Welch et al. (1996) Gene Therapy 3:994).
- One goal of this technology is to start with a "library" of ribozymes, containing all possible target recognition sequences and select and enrich for specific ribozymes most active at inactivating the expression of a specific gene or ablating a specific gene function in vivo.
- the particular phenotype and the method of measuring it vary with the kind of gene under examination.
- the effects of ribozymes on nucleic acids that encode receptors e.g., hormone or drug receptors, such as platelet-derived growth factor receptor ("PDGF r ") is measured in terms of differences of binding properties, differentiation, or growth.
- Effects on transcription regulatory factors are measured in terms of the effect of ribozymes of transcription levels of affected genes.
- Effects on kinases are measured as changes in levels and patterns of phosphorylation.
- Effects on tumor suppressors and oncogenes are measured as alterations in transformation, tumorigenicity, morphology, invasiveness, adhesiveness and/or growth patterns.
- the list of type of gene function and phenotype that is subject to alteration goes on: viral susceptibility - HIV infection; autoimmunity - inactivation of lymphocytes; drug sensitivity drug toxicity and efficacy; graft rejection- MHC antigen presentation, etc.
- the iigated ribozymes now can be selectively amplified out of the library.
- the second preferred method is to immobilize the target RNA on a solid support, thus allowing soluble ribozymes to be selected based on their ability to bind, cleave and elute off of the target.
- the target can be any RNA (e.g. cellular or viral RNA), or DNA that has been converted to RNA. It is preferable to immobilize the target RNA by its 5' end (see below), but RNA immobilized via its 3' end is also suitable.
- the hairpin ribozyme is capable of cleaving a target RNA in both a cis and trans configuration (Bruening et al (1988) Structure and Expression, Vol. 1 , p.239-248; Hampel et al (1988) Biochemistry 28:4929).
- This ligation reaction can be applied in the generation of target specific libraries.
- An elegant and efficient method for accomplishing this task is to make use of the ribozyme as a molecular tag.
- This ribozyme tag will provide a universal upstream primer for the subsequent isolation and amplification of the reaction products. This will facilitate the identification and sequence determination of the unique cleavage sites present within the target RNA and be used to generate a target specific ribozyme gene vector library.
- the ribozyme must be capable of catalyzing trans-ligation at the site of cleavage within the target RNA. This can be accomplished by designing a combinatorial ribozyme library that first undergoes an autolytic cleavage. This self-processed library is then incubated in a trans-cleavage reaction with the target RNA of interest and, with a certain frequency, the ribozyme will become covalently attached to the target RNA at the site if cleavage through trans-ligation ( Figure 10). Specifically, a ribozyme combinatorial library will be constructed wherein the inter-molecular helices I and II will be completely randomized.
- This library will also contain, attached to its 3' end, a completely randomized cis-cleavage site having only a 3bp helix I and helix II.
- the cis -cleavage site is tethered to the 3' end of the ribozyme by means of a 5bp polypyrimidine tract.
- the ribozyme library is transcribed and concurrently will undergo the cis-cleavage reaction. This will generate a pool of randomized ribozymes also having a randomized helix II cleavage product still attached to the ribozyme. The presence if this helix II cleavage product is important for two reasons.
- This pool of 'helix II charged ribozymes' is then purified from the rest of the library and used in a trans-cleavage reaction with the target RNA under standard cleavage conditions. The ribozyme will cleave the target at specific sites and, with a certain frequency, the ribozyme will become covalently attached to the target RNA at these sites by means of the trans-ligation reaction ( Figure 10).
- the identification of these unique cleavage sites is then determined by RT-PCR.
- the reaction products from the trans-cleavage reaction are reacted with polyA-polymerase to generate a polyA tail on the 3' end of the reaction products.
- the RNA is then reverse transcribed using oligo-dT as the primer.
- This resulting cDNA is then amplified by PCR using the oligo dT as the downstream primer and a universal upstream primer provided by the Iigated ribozyme sequence.
- the reaction products are amplified by PCR and can be sequenced directly or after subcloning.
- the selected ribozyme genes are further cloned into AAV vectors.
- the target RNA has a 5' methyl-G cap (such as cellular mRNA and many viral RNAs)
- the RNA can be immunoprecipitated using monoclonal antibodies directed against the cap structure (Garcin and Kolakofsky, 1990; Weber, 1996) and immobilized on Protein G sepharose beads (Pharmacia, Uppsala, Sweden) (see Figure 7).
- the target RNA is not capped (such as some viral RNAs, non-messenger cellular RNA or RNA transcribed in vitro), it can be bound to streptavidin-agarose beads (Pierce, Rockford II) via a 30-mer oligonucleotide that is biotinylated at its 3' end (see Figure 7).
- the sequence of the 30-mer is complementary to the 5' end of the target RNA.
- the target is a known viral or cellular RNA
- the oligo is designed based on the known sequence of the RNA's 5' end.
- the target RNA comes from genomic DNA of unknown sequence that has been converted to RNA via retrovirus packaging, the oligo is designed based on the retroviral-specific immediate 5' sequence transcribed from the LTR.
- DNA cloned into in vitro transcription vectors and transcribed by T7 RNA polymerase to yield the target are engineered to contain specific 30 nt at their 5' end, upstream of the actual target sequence.
- the 3' end of the specific 30-mer biotinylated oligo is bound to the streptavidin column and the 5' 30 nt bind the target RNA by Watson-Crick base pairing (see Figure 7).
- the biotinylated oligo is incubated with the beads and unbound oligo is washed out.
- the target RNA is then mixed with the oligo column, heated to 95° C and cooled slowly to allow annealing of the oligo and target RNA.
- the column is then washed to remove unbound target RNA..
- the target RNA it is occasionally necessary to immobilize the target RNA by its 3' end. If the target RNA is polyadenylated mRNA, a simple oligo d(T)3 Q column would bind the target RNA (Pharmacia) ( Figure 7). If the target RNA is not polyadenylated (or if one wishes a stronger binding than simple Watson-Crick basepairing), the 3' end of the RNA can be biotinylated using biotin-UTP (Sigma, St. Louis, MO) and terminal transferase (Promega, Madison, Wl), according to the manufacturers. The biotinylated target can then be immobilized on streptavidin-agarose beads (Pierce, Rockford II) ( Figure 7).
- biotin-UTP Sigma, St. Louis, MO
- terminal transferase Promega, Madison, Wl
- This application involves the use of a library of randomized ribozymes as opposed to randomized ribozyme genes, in vitro synthesis of the ribozymes encoded by the library is accomplished by transcribing the double-stranded ribozyme gene library (described in Specific Example a.) with T7 RNA polymerase, as described (Welch, P.J., et al. (1996) Gene Therapy 3:994-1001 ). For later tracking and selection purposes, the ribozyme library can be transcribed in the presence of trace amounts of P-32 UTP. The ribozyme library transcription reaction is then treated with DNase to remove the DNA template.
- transcribed ribozymes are purified by polyacrylamide gel to enrich for full length transcripts.
- the ribozymes can be radio-labeled with t P]UTP, which can be used as a marker to follow the binding of the ribozymes at various stages of selection (see below).
- RNA target column is pre-treated with non-specific RNA (such as E. coli rRNA or yeast tRNA), the ribozymes are loaded in the absence of magnesium, and the unbound non-specific RNA washed from the column ( Figure 8). This reduces non-specific binding of ribozyme to the column.
- the ribozyme library is then added to the RNA target column along with non-specific RNA, again in the absence of magnesium, thus allowing ribozyme binding without actual cleavage of the target RNA (Ojwang et al. (1992) Proc. Natl. Acad. Sci. USA 89: 10802).
- the ribozyme library can be transcribed in the presence of trace amounts of P-32 UTP, thus allowing quantitation of ribozyme binding and release throughout all the selection steps.
- the ribozyme library is added such that the target RNA is in molar excess, otherwise more than one ribozyme will be released from the column following a successful cleavage, generating false-positive results.
- the column is then washed free of unbound ribozyme. Specific ribozyme binding can be monitored by following the radioactivity remaining bound to the column.
- ribozyme cleavage buffer is then added to the column and the slurry is incubated at 37 °C for two hours to allow for substrate cleavage to occur.
- a ribozyme successfully cleaves the target, it temporarily acts as a "bridge" between the 5' and 3' substrate products. Since the 5' product is bound by only a 4 bp helix, this interaction rapidly melts at 37 ° C and the ribozyme is released from the solid support ( Figure 8). If the target RNA is immobilized via its 3' end, the cleaving ribozyme remains bound by the 7 bp helix, which will also rapidly melt at 37 ° C (max T m ⁇ 22 ° C).
- ribozymes are ones with activity against the target. These are then eluted and precipitated for amplification. Again, the specificity of the binding and cleavage reactions can be monitored by following the radioactivity present in the transcribed ribozymes. For proof that the selection procedure is successful, the initial library can be "spiked” with a known amount of purified ribozyme with known activity against the target (if available).
- Reverse transcriptase is used to convert the selected ribozyme pool to DNA using a primer specific to the 3' end of all the ribozymes (3' Primer).
- This primer includes the Mlul site and a portion of the common region of the ribozyme and is therefore present in all ribozymes which were made in the library.
- the reverse transcriptase products are then amplified by standard PCR using a primer specific for the 5' end of all ribozymes in the library including a BamHI restriction site (5' Primer).
- This 5' primer used in this amplification step may or may not also include (at its 5' end) a T7 promoter arm for a future transcription steps.
- the PCR products are then purified and transcribed with T7 RNA polymerase.
- the resulting "selected" ribozymes are gel purified, and then used for a second (third, fourth, etc.) round of further selection on a fresh target column, bound, allowed to cleave and subsequently eluted and amplified as above until only specific, active ribozymes remain in the pool.
- Ribozyme binding and activity is continually monitored by following the location of the radiolabeled pool of ribozymes, and this is also used as a measure of specificity of the selection. For example, with an unselected pool of ribozyme the majority of the radiolabei will not even bind the column. Conversely, with a highly selected pool, most of the radiolabei would initially bind the column and then most would be released once magnesium was added.
- Ribozyme transcription, binding and selection is performed in one day.
- the subsequent PCR amplification products do not contain any radioactive nucleotides, and are therefore stable for long periods of time. Together, the combination of high-specificity binding and subsequent PCR amplification allows for conditions that are both selective and of high yield. vii. Ribozyme cloning, sequencing, identification of sites and target gene cloning
- each specific ribozyme is cloned from its amplified double-stranded DNA template into a sequencing vector (e.g. , pGem7Z, Promega) via the BamHI and Mlul sites.
- a sequencing vector e.g. , pGem7Z, Promega
- Each ribozyme clone is then sequenced and the resulting sequence of the ribozyme binding arms is used to identify the site within the target (if the target sequence is known) or to generate a DNA probe to clone the target gene (if the gene is unknown).
- the sequence of the ribozyme binding arms is combined with the requisite GUC to construct a DNA probe 5'XXXXXXNGUCXXXX3' (where X is the deduced sequence coming from the specific ribozyme), which is then used to screen cDNA libraries to clone the gene.
- the selected ribozymes are then applied to another column prepared with the RNA target bound to the column in the reverse orientation (i.e. if target bound on 5' previously, then switch to 3' immobilization). This re-screening and amplification is repeated as many times as necessary to satisfy pre-determined requirements set for the ribozymes to be selected (i.e.
- the ribozyme genes are cloned into AAV vectors, resulting in a specific ribozyme gene vector library (see previous and later sections for cloning and application).
- the ribozyme fragment generated after PCR amplification contains BamHI and Mlul restriction sites (see 5' Primer and 3' Primer).
- this library of AAV-ribozyme can be used for a variety of applications including, but not limited to, therapeutic and gene functional analysis in vivo.
- a procedure called "sub-tractive hybridization” would be employed to determine which genes are differentially expressed (for review Ausubel, F., et al. (ed.) (1987) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing and Wiley-lnterscience, New York. Briefly, mRNA or cDNA from each cell type are mixed and allowed to hybridize. The hybridized products (dsRNA or dsDNA) are then removed by column chromatography and the remaining, unhybridized nucleic acids (the differentially-expressed genes) are cloned.
- the main disadvantages, among others, of this method lies in its technical difficulty and its time consuming procedures.
- the randomized ribozyme library of the present invention is used in vitro to both identify differentially-expressed genes and to generate specific, active ribozymes against the unique mRNAs.
- mRNA is isolated from the two different cell lines in question (cell A and cell B).
- Individual target RNA columns are prepared for each cell type by either: a) binding the mRNAs by their 5' ends using a monoclonal antibody directed against the 5' methyl-G cap (for detailed discussion see above section on identification of ribozymes that cleave a known target RNA), bound to protein G-sepharose or b) binding the mRNAs by their 3' polyadenylated tails to an oligo(dT) column (again, see detailed discussion in identification of ribozymes that cleave a known target RNA).
- the ribozyme library is synthesized by in vitro transcription and applied to the column prepared from the mRNA of cell A under conditions that inhibit cleavage such as the absence of magnesium or low temperature (thus allowing ribozyme binding but not cleavage). Ribozymes that flow through this column represent targets not present in the mRNA pool of cell A. The bound ribozymes are then allowed to cleave by changing the conditions to favor cleavage (i.e. add magnesium or increase temperature). Active, specific ribozymes are then released from the solid support. Ribozymes that are released at this step are ones capable of both binding and cleaving RNA from cell A.
- ribozymes are then applied to the RNA column from cell B under conditions that prevent cleavage.
- These cell A-specific ribozymes that also bind the cell B column represent ribozymes that recognize RNA targets present in both cells, while the ribozymes that flowthru are ones that recognize RNA only expressed in cell A.
- These ribozymes are then amplified, cloned and sequenced to produce a probe to clone the differentially-expressed, cell A-specific genes.
- the specific ribozymes are cloned into AAV vectors which can be applied to cell A to analyze the effects and function of the differentially-expressed genes.
- the above described process can be reversed (i.e. apply ribozymes to column B first then column A) to isolate genes differentially expressed in cell B.
- differential display could be used to generate RNA fragments specific for one cell type, and these RNA's could then be used to generate a target specific library.
- Transduction with the full ribozyme gene library can result in the expression of ribozymes directed against essential cellular genes. Cells expressing such "toxic" ribozymes will die. This is an especially important consideration when more than one ribozyme is delivered per cell, since the presence of a "toxic" ribozyme would automatically select out any other ribozyme genes in that same cell.
- the full library is transduced into the host cells, preferably at an m.o.i. of less than 1 , and the ribozyme genes of surviving cells are rescued. The new library of rescued ribozyme genes encodes ribozymes that are not fatal to the host cell.
- This new library can be used to transduce host cells to detect in vivo ribozyme effects, or it can be used to screen for active ribozymes in vitro as described above. Additionally, this "pre-selection" is a particularly important screening step when it is necessary to introduce multiple ribozyme genes into one cell. 3. Specific examples
- Ribozyme genes with randomized recognition sequences were synthesized as follows: A 5'Primer (containing the T7 promoter, a BamHI restriction enzyme site and a region complementary to a 3' Synth Primer) was annealed to a 3' Synth Primer (which consists of an Mlu I restriction enzyme site, the catalytic region of the ribozyme, the randomized binding arms and a region complementary to the 5'Primer) and the single-stranded regions were converted to double-stranded DNA.
- the nucleic acids comprising randomized ribozyme binding arms recognize the following target sequences: (N) 4 N*GUC(N) 6 _ 1 0 or (N) 4 N*GUA(N) 6 _ 1 0 (* denotes the cleavage site, and N can be any nucleotide).
- These oligonucleotides were synthesized in vitro by Retrogen (San Diego, CA). After synthesis, the oligonucleotides were purified as described previously. (Welch, P.J. et al. (1996) Gene Therapy 3:994-1001 ).
- the specific ribozyme oligonucleotide (3' synth primer, 1 -2 g) was hybridized to the corresponding oligonucleotide (5' primer, 2-5 ⁇ g) and the single-stranded regions were converted to double-stranded DNA using Klenow DNA polymerase (Promega, Madison, Wl, USA).
- Klenow DNA polymerase Promega, Madison, Wl, USA.
- the completed double strand ribozyme library was amplified by PCR to increase the copy numbers of each ribozyme representative using purified 5' Primer and 3' Primer.
- the amplified ribozyme gene library was transcribed in vitro to test the ribozyme library complexity by T7 polymerase (20-40 Units) as described in Welch, P.J. et al., (1996) Gene Therapy 3:994-1001 ).
- the ribozyme library complexity was tested by cleaving known ribozyme target sites [found in HIV and HCV RNA sequences] ( Figure 2).
- the final library comprised about ⁇ 4 x 10 individual species.
- the specific ribozyme library oligonucleotides contain an Mlul restriction site, and the corresponding oligonucleotide contain BamHI restriction enzyme site.
- two different approaches were used. In the first approach, a ribozyme gene library was generated by PCR and then subcloned and Iigated into the AAV vector cassette. However, since ligation may be inefficient and may also result in incorporation of multiple inserts, a second approach for engineering the AAV random ribozyme vector library was to incorporate the ribozyme gene library into the vector directly by using "PCR cloning."
- pAMFT.dBam ( Figure 3)(modified from psub201 (Samulski R.J. 1987. J. Virol. 61 : 3096-3101 ), was used in the first approach for ribozyme library gene cloning.
- pAMFT.dBam is a recombinant plasmid carrying 1 ) 5' and 3' inverted terminal repeats (ITR) of adeno-associated viral genome; 2) cassette for transcription and translation of gene of interests; 3) neomycin resistance marker pAMFT dBam (50 ⁇ g, 81 29bp) was thoroughly digested overnight at 37° C with restriction enzymes BamHI and Mlul (200 Units each) .
- the digestion reaction were terminated (and purified by phenol-chloroform extraction and the desired gene fragments isolated from agarose gel after gel electrophoresis.
- the in vitro synthesized ribozyme genes were also digested with BamHI and Mlul, and inserted to BamHI and Mlul restricted pAMFT dBam by ligation ( 200 Units of ligase) at 1 5° C overnight. To increase the ligation efficiency of ribozyme gene insert into vector, several precautions were taken.
- Recombinant AAV (rAAV) are produced by transient transfection of cells at 90% confluency in flat stock.
- pAAV/Ad helper plasmids that provide rep and cap proteins in trans were a kind gift of J. Samulski.
- the AAV ribozyme library pro-vector plasmids (pAMFT.dBam-ribozyme lib) are cotransfected with the pAAV/Ad helper at a ratio 1 : 1 using LipofectAmine (Life Technologies Inc.). Since low efficiency of co-transfection can account for low AAV titer, transfection of Hela cells with LipofectAmine were optimized (Table 2).
- Hela cells were transfected with 3 forms of DNA, 1 ) linear 2) closed after self ligation and 3) supercoil DNA induced by topoisomerase.
- the cells are infected with adenovirus type 5 (Ad5) at an MOI of 5-10 and harvested on day 4.
- Cells are lysed by nebulization and clarified by hollow fiber microfiltration followed by a concentration step using ultrafiltration. Clarified lysate is purified using a dual column chromatography process.
- the action exchange resin HS removes the majority of the contaminating proteins and DNA, the rAAV peak is eluted of in phosphate buffer pH 7.2, 300 mM NaCI, and immediately loaded on the anion exchange resin HQ (Perseptives, Inc.) where the adenoviral contamination is removed.
- the flow through is collected and heat inactivated at 56° C for 2 hours to ensure the inactivation of any residual adenoviral contamination.
- the purified rAAV is formulated for storage.
- the final product is tested for infectious titer, particle titer, residual DNA and protein, adenoviral contamination, and wild type AAV.
- Purified product from packaging cells is compared for quality and consistency in each test.
- Particle titer is determined by a slot blot procedure using radiolabelled probe and quantitated using a plasmid standard curve and previously titered vector.
- Adenoviral contamination is determined by plaque assay (Graham and Van Der Eb (1973) Virology 42:456-467) following three amplification cycles on permissive cells. This assay is sensitive to ten infectious particles per milliliter.
- Wild type AAV is tested by QC-PCR analysis following three amplification cycles in the presence of adenovirus on permissive cells. This assay is sensitive to ten infectious particles per milliliter.
- Dilutions of the heat inactivated rAAV lysate are added to 1 x 10 5 HeLa cells/well plated in 6 well dishes.
- Titers of AAV-ribozyme-Lib preparations are determined by resistance to G41 8 as neo titer.
- High-titer (1 x 10 particles/ml) preparations are stored at 80° C until use.
- a second approach for generating the AAV random ribozyme vector library is to incorporate the random ribozyme gene library into the pAMFT.dBam vector by using multiple rounds of PCR, as illustrated in Figure 4.
- a "mega primer” is generated in a first round of PCR which comprises an AAV 3'-ITR, a tRNA val promoter and ribozyme library genes, using the primers set 1 and 1 listed below:
- the resulting PCR product is purified and used as 5'-megaprimer (AAV-ITR-tRNA-ribozyme library) for a second round PCR to generate the full length AAV vector with ribozyme library gene.
- AAV-ITR-tRNA-ribozyme library 5'-megaprimer
- the resulting DNA is linear, it may require autoligation via the Bgl II Site and/or supercoiling by topoisomerase.
- the resultant linear form of AAV pro-vector ribozyme gene DNA are purified, and used to generate AAV vector.
- the entire AAV-ribozyme expression cassette can be easily "rescued” from the host cell genome by introduction of the AAV viral proteins and wild type adenovirus. This makes isolation, purification and identification of selected ribozymes considerably easier than other molecular biology techniques, all without replication-competent virus.
- the HIV targets and the HCV target were pol3308 and env7931 and HCV core506, respectively (Townsend and Townsend case No. 01 6556-000800, Immusol, Inc., Novel Anti-HIV Ribozymes, Leavitt et al.; Welch et al. (1996) Gene Therapy 3:994). These were transcribed at 37° C for 2 hr by using MEGA script High yield Transcription kit(Ambion Inc., Austin, Tx):
- the DNA template was removed by incubating with 1 I RQ1 RNAse free DNase (Promega) at 37° C for 1 5-30 min. Samples were denatured at 65-70° C for 5 minutes prior to loading onto a (5% polyacrylamide/7 M urea gel for purification. The transcripts of target were excised form the gel by UV shadowing technique, and further extracted by BIO 101 RNaid kit (BIO 101 , San Diego CA).
- Ribozyme library was transcribed in vitro and gel purified as described above, in the absence of [ 32 P]CTP.
- Ribozyme/substrate in vitro cleavage was carried out by incubating equimolar amounts of ribozyme library transcript with substrate RNA at 37° C for 1 -3 hour in 40 mM Tris, pH 7.5, 12 mM MgCI 2 / 2 mM spermidine/ 0.2 mM EDTA. Reactions were terminated by the addition of 1 vol. of 2 x loading buffer (80% formamide, 0.1 % bromophenol blue, 0.1 % xylene cyanol, 2 mM EDTA). Products of the cleavage reactions are resolved by electrophoresis on 1 5% acrylamide/7M urea gels and analyzed by autoradiography.
- the ribozyme library contains a high degree of sequence complexity as determined by its ability to cleave three different RNA substrates known to be cleavable by corresponding ribozyme.
- Transfection efficiencies were tested on several candidate cell lines, including Hela, 293, A549, CF2, MDCK, and CHO with five commercially available lipid preparations compared to CaPO ⁇ using an NGFR reporter plasmid.
- Two lipids, LipofectAmine (GIBCO/BRL) and DOSPER (Boehringer Mannheim) showed the highest transfection efficiencies on HeLa, 293, A549 and Cf2, using AAV/NGFR and Ad8 in our experimental system followed by FACS analysis as shown in Table 2.
- AAV particle generation by transient transfection is optimized to yield the highest possible AAV titer with a minimum amount of DNA. This step is crucial for assuring a vector gene library with maximal sequence complexity.
- ribozyme gene vector libraries are generated by transient transfection on AAV packaging cell lines and purified by column chromatography. Column purification is carried out only if necessary for optimal transduction efficiency and depending on the desired application.
- Vector is then applied to a given cell and the desired phenotype is analyzed. Ribozyme sequences in the transduced cells are identified, amplified and rescued with wild type AAV or helper plasmids and helper virus (such as adenovirus). The rescued vector is then used again to transduce the target cells and the cycle repeated.
- AAV and adenovirus can be selectively inactivated or purified. Any remaining wild type AAV will be inert since it cannot replicate without a helper virus.
- Immusol, Inc. has previously developed the technology of "increased titer of recombinant AAV vectors by gene transfer with adenovirus coupled to DNA polylysine complexes". This method was published in GENE THERAPY (vol.2, pp429, 1995). This technology is licensed to Immusol and has been used as our routine rAAV preparations for all pre-clinical studies. Recently this technique has been adapted to large-scale preparation of purified rAAV at high titer using CsC ⁇ centrifugation (Table 3)
- Peak titers o are in excess of 5 x 10°/ml (neo colony forming units, CFU). The total yield o from a single prep is more than 5 x 109 CFU at an average titer of 1 x 10 CFU/ml (Table 3 and data not shown).
- rAAV-NGFR cell lysate was used that had already been frozen/thawed 6 times. Centrifuged (C) and uncentrifuged (U) lysate were frozen and thawed once (C1 andUD, twice (C2 and U2), and three times (C3 and U3) by setting them into the -80C for 1 .5 hours and then quick thawing(by swirling) in a 37C water bath. HeLa cells were transduced with 20/vl and 80/vl of each sample and rAAV-NGFR activity was analyzed by FACS on Day 2. It appears that the rAAV vector can withstand up to 10 freeze/thaw steps stored as either centrifuged or uncentrifuged cell lysate (Table 4).
- rAAV-NGFR vector was treated with either Benzonase or DNase.
- Benzonase or DNase To 100 ⁇ of the vector was added: 1 ⁇ l 1 M MgCI2 and 1 ⁇ l Benzonase( 280U/ ⁇ l).
- To another 100 ⁇ of the vector was added: 1 ⁇ l 1 M MgCI2 and 1 ⁇ l RQ1 DNase (1 U/ ⁇ l).
- Target cells are generated that express the target RNA of interest. If the product of the target gene itself is FACS-sortable (i.e. any cell surface protein that is detectable by a specific antibody) or is selectable by various culturing methods (i.e. drug resistance, viral susceptibility, etc.), then one can proceed directly to application of the vector library below. If not, then the target gene sequence is cloned in cis to two separate reporter genes that are either FACS-sortable and/or selectable, for example the green fluorescent protein (GFP) or the nerve growth factor receptor (NGFR) that are FACS-sortable and HSV thymidine kinase (tk) that renders a cell sensitive to gancyclovir. These two target-reporter constructs are then stably transfected into cells (e.g. HeLa or A549) to create the target cells.
- FRP green fluorescent protein
- NGFR nerve growth factor receptor
- tk thymidine kinase
- the AAV vectors in which the ribozyme library is embedded contain a neo r gene as a selection marker and for titering purposes.
- Target cells are grown to 70-80% confluency and transduced with the AAV-ribozyme library at an m.o.i. > 1 (to favor multiple transduction events, and multiple ribozyme genes, per cell).
- Transduction is accomplished by incubating cells with vector overnight at 37° C, as described above.
- Transduced cells are selected by culturing the cells for 10-14 days in the presence of G418 (400-500 micrograms/ml culture medium).
- the ribozyme vectors present in these surviving cell clones are rescued from the cell by wild type AAV or by transient transfection with packaging plasmids in the presence of adenovirus (Harmonat and Muzyczka (1984) Proc. Natl. Acad. Sci. USA 81 :6466; Tratschin et al. (1985) Mol. Cell. Biol. 5:3251 ; Samulski et al (1982) Proc. Natl. Acad. Sci. USA 79:2077).
- the rescued vectors are then re-introduced into the untransduced parental cell line under conditions favoring a single ribozyme pro-vector per cell, and reselected or screened.
- the corresponding ribozyme gene found within the cell line is PCR cloned and sequenced using PCR primers described herein.
- the resulting sequence is expected to be exactly complementary to the gene sequence the ribozyme is inactivating, except that the target RNA must also contain a GUC sequence.
- the sequence of the leptin gene and of the promoter regions of the leptin gene have been described (Miller et al. (1996) Proc. Natl. Acad. Sci. USA 93:5507).
- the transcriptional promoter elements of the leptin gene are PCR cloned directly from known sequence information. They may also be obtained from sources such as the American Type Tissue Culture Collection.
- Expression vectors are generated whereby either of two reporter genes, NGFR or GFP, are expressed from the leptin promoter.
- Stable reporter gene-expressing cell lines are derived as described above and selected for expression of NFGR and GFP by Fluorescence-Activated Cell Sorting (FACS) analysis.
- FACS Fluorescence-Activated Cell Sorting
- Clones are selected which express uniform levels of both markers, as homogeneous populations, to yield good signal-to-noise ratios during FACS analysis to facilitate subsequent identification of underexpressing cells. Such clones are obtained by isolating transduced cells that exhibit a uniform level of fluorescence using by FACS, and then cloning these cells.
- Cell clones are transduced with the AAV random ribozyme gene vector library at a high multiplicity of infection (m.o.i. > 1 ) and selected in G418. Cells expressing both reporter genes are then selected by FACS analysis and under-expressing and over-expressing clonal cell lines are generated, since any alteration in reporter gene expression may indicate a target responsible for leptin gene regulation. Since these cell clones are isolated from cells that were transduced at a high multiplicity of infection, many contain multiple ribozyme genes. AAVs that contain ribozyme genes are rescued from the different under-expressing or over-expressing cell clones as described above (Section 2.b.iv.a).
- each clonal cell line expresses only a single ribozyme gene. The presence of a single ribozyme gene is confirmed by rescue of the AAV genome and sequence analysis of the ribozyme gene(s).
- ribozyme genes that cause under-expression or over-expression of reporter genes that are operably linked to the leptin promoter are then transduced into cells that express the leptin gene itself.
- Individual clonal isolates are screened for expression of the leptin gene by RNase protection and protein immunoblot assays (Sambrook, et al.). Activity of specific ribozymes is verified using the corresponding disabled ribozyme (mutation of loop 2 AAA to UGC, see Section 2.f) Cell clones with altered leptin gene expression are selected for further study.
- the sequence of the ribozyme binding arms is combined with the requisite GUC to construct a DNA probe (5'XXXXXXXNGUCXXXX3', where X is the deduced sequence coming from the specific ribozyme), which is then used to screen cDNA libraries (Sambrook et al) to clone the gene or genes whose inactivation modulates leptin expression.
- Cip 1 also known as Cip 1 (CDK-interacting protein) is a negative regulator of mammalian cell cycle progression.
- Overexpression of human P21 efficiently arrests vascular smooth muscle cells (VSMC) in the G- j phase of the cell cycle and results in a 60% reduction in VSMC proliferation following growth factor simulation in vitro (Chang er a/., 1995 J. Clin. Invest. 96: 2260-2268).
- Genes involved in p21 gene expression are identified by a protocol similar to that described for leptin gene regulation, except the p21 promoter elements will be used to drive the expression of the reporter genes, NGFR or GFP.
- Individual ribozyme genes that cause under-expression of the reporter genes are used to isolate genes that activate the cell cycle, while those ribozymes that cause over-expression of reporter genes can be used to identify genes that transrepress cell cycle.
- the cells are primary cells with no tumor phenotype or partially transformed or immortalized cells that show little to no tumor growth in nude mice (O'Toole et al. (1978) Br. J. Cancer 38:64; Ponten et al. (1971 ) Hum Hered. 21 :238). selecting cells that were transduced by the AAV-ribozyme using G418 selection (AAV carries neomycin resistance gene). plating all transduced cells in soft agar, to assay anchorage dependence (Renshaw et al. (1995) Mol.
- ribozymes Once specific ribozymes have been selected, their activity is verified to be due to RNA cleavage and not simply antisense as previously described.
- the selected ribozyme genes are amplified by PCR, cloned and sequenced.
- the sequence of the ribozyme binding arms is combined with the requisite GUC to construct a DNA probe (5'XXXXXXNGUCXXXX3', where X is the deduced sequence coming from the specific ribozyme), which is then used to screen cDNA libraries to clone the gene whose inactivation results in tumor formation.
- Identification of an unknown gene responsible for tumorigenesis is accomplished by: transducing isolated primary tumor cells or any transformed cell line with AAV-ribozyme library; selecting cells that were transduced by the AAV-ribozyme using G418 selection (AAV carries neomycin resistance gene); plating the selected cells and allowing them to reach confluence; treat the confluent cultures with bromo-deoxyuridine (BrdU), a nucleoside analog that is toxic to any cell that is actively dividing. All cells that remain non-contact inhibited in the culture will die. Cells that received a ribozyme gene that inactivates the oncogene responsible for the tumorigenesis will not be growing in a confluent culture due to contact inhibition. Untransformed cells are contact inhibited and are arrested in quiescence, transformed cells are not and will continue to grow on top of each other as long as they are fed;
- Programmed cell death or apoptosis is essential for normal development. Deregulation of apoptosis can lead to a spectrum of defects ranging from embryo lethality, to perturbation of post-natal development and even to cancer. Identification of genes that modulate the regulation of apoptosis provides an opportunity for the treatment of numerous diseases including cancer, neuronal degeneration, lymphoproliferation, inflammation and immunodeficiency, among others.
- Apoptosis can be triggered in a variety of ways, depending on the cell type (for review see McConkey et al (1996) Molecular Aspects of Medicine 1 7: 1 ).
- the AAV ribozyme gene vector library is transduced into appropriate cells and selected with G418. The cells are then triggered to undergo apoptosis. Any cells that subsequently survive are grown up and the ribozyme gene or genes responsible are cloned out of the rescued AAV vectors (as described in the previous sections. Genes involved in the apoptotic pathway can then be cloned, again based on the sequence of the ribozyme binding arms and GUC (see above sections).
- Apoptosis can be measured by numerous ways. Loss of cell viability (failure to either excluded vital dye or uptake MTT), DNA fragmentation (assayed by) agarose gel electrophoresis, PFG electrophoresis, in situ tunnel (terminal transf erase labeling), cell and nuclear morphology (microscopy to visualize chromatin condensation, DNA organization, and cytoplasmic integrity), cysteine protease activation (PARP or lamin cleavage in vivo or in vitro, an inhibition by cysteine protease inhibitors), sub G1 peak by FACS analysis, and inhibition by Bcl-2, are some of the means for measuring apoptosis.
- ICE gene family (lnterieukin-1 (Converting Enzyme). Mutations of ced-3/ICE gene prevent apoptotic death in cells and overexpression if ICE gene in a number of cell types induce apoptosis (Thornberry, N.A. et al., 1992. Nature 356:768-774; Miura, M. et al., 1 993. Cell 78:653-660; Gagliardini, V. et al., 1994. J. Biol. Chem. , 268:826-828).
- HPVs are present in many anogenital tumors, including anal, penile, vagina, and vulvar cancers.
- the transforming effects of the proteins of HPVs are mediated through interactions with cellular proteins.
- the E6 protein of the "high risk" HPVs binds to the tumor suppressor p53 protein, and hastens its degradation (ref).
- the E7 protein can cooperate with an activated ras oncogene (ref), binds to a tumor suppressor, the cellular retinoblastoma gene product (pRB) and inhibits its function.
- the expression of the transforming genes of HPVs is controlled by both viral and cellular factors.
- the major regulatory region in the genome is the upstream regulatory region (URR).
- Sites that have been identified and located in the URR include binding sites of the cellular factors P92, Sp1 , Ap1 , Oct-1 , Ap2, TEF-1 , PR, NFA, and PVF. Cellular factors that act at these sites have been studied in cervical epithelium, and probably have equivalents in other epitheiia (ref).
- 5'-AAV-ITR primer 5'-AGGA ⁇ G rC7CAGCAGCTGCGCGCTCGCTCGCTCACTGAGG-3'
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/355,221 US6605429B1 (en) | 1997-01-23 | 1998-01-21 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
JP53211498A JP2002514914A (en) | 1997-01-23 | 1998-01-21 | Analysis and discovery of gene function using randomized or target-specific ribozyme gene vector libraries |
CA002278734A CA2278734A1 (en) | 1997-01-23 | 1998-01-21 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
EP98902675A EP0996741A4 (en) | 1997-01-23 | 1998-01-21 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
AU59275/98A AU5927598A (en) | 1997-01-23 | 1998-01-21 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
US10/613,565 US20040096818A1 (en) | 1997-01-23 | 2003-07-02 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3735297P | 1997-01-23 | 1997-01-23 | |
US60/037,352 | 1997-01-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/355,221 A-371-Of-International US6605429B1 (en) | 1997-01-23 | 1998-01-21 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
US10/613,565 Division US20040096818A1 (en) | 1997-01-23 | 2003-07-02 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998032880A1 true WO1998032880A1 (en) | 1998-07-30 |
Family
ID=21893885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/001196 WO1998032880A1 (en) | 1997-01-23 | 1998-01-21 | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
Country Status (6)
Country | Link |
---|---|
US (2) | US6605429B1 (en) |
EP (1) | EP0996741A4 (en) |
JP (1) | JP2002514914A (en) |
AU (1) | AU5927598A (en) |
CA (1) | CA2278734A1 (en) |
WO (1) | WO1998032880A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050530A2 (en) * | 1997-05-09 | 1998-11-12 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids: synthesis, selection and use |
WO1999027135A2 (en) * | 1997-11-21 | 1999-06-03 | Yale University | Method for identifying and inhibiting functional nucleic acid molecules in cells |
WO1999032618A1 (en) * | 1997-12-19 | 1999-07-01 | Strata Biosciences Incorporated | Non-bacterial cloning in delivery and expression of nucleic acids |
WO1999041371A1 (en) * | 1998-02-13 | 1999-08-19 | Genetrace Systems, Inc. | Use of ribozymes for functionating genes |
WO1999053031A2 (en) * | 1998-04-08 | 1999-10-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Process for producing cell clone libraries |
WO2000005406A1 (en) * | 1998-07-20 | 2000-02-03 | M & E Biotech A/S | Novel methods for the identification of ligand and target biomolecules |
WO2000044894A1 (en) * | 1999-01-29 | 2000-08-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for isolating apoptosis-inducing dna sequences and detection system |
US6127535A (en) * | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
EP1041144A1 (en) * | 1999-03-29 | 2000-10-04 | Michael Blind | Methods for the identification and validation of functional intracellular targets with intramers or in vivo selection |
WO2000066780A2 (en) * | 1999-04-30 | 2000-11-09 | University Of Florida | Adeno-associated virus-delivered ribozyme compositions and methods of use |
WO2001000869A2 (en) * | 1999-06-23 | 2001-01-04 | Intelligene Ltd. | Arrays of catalytic or pre-catalytic nucleic acids |
US6183959B1 (en) | 1997-07-03 | 2001-02-06 | Ribozyme Pharmaceuticals, Inc. | Method for target site selection and discovery |
EP1097244A1 (en) * | 1998-07-22 | 2001-05-09 | Immusol, Inc. | Substantially complete ribozyme libraries |
US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
WO2001044513A2 (en) * | 1999-12-16 | 2001-06-21 | Iconix Pharmaceuticals, Inc. | Random domain mapping |
US6280936B1 (en) | 1997-06-09 | 2001-08-28 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
WO2001083754A2 (en) * | 2000-05-02 | 2001-11-08 | Immusol, Incorporated | Cellular regulators of infectious agents and methods of use |
US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
EP1187845A2 (en) * | 1999-11-12 | 2002-03-20 | Immusol, Inc. | Tumor suppressor molecules and methods of use |
WO2002063037A2 (en) * | 2001-02-02 | 2002-08-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying functional nucleic acids |
EP1270746A1 (en) * | 1998-07-20 | 2003-01-02 | Inoxell A/S | Methods for the identification of ligand and target biomolecules |
US6548657B1 (en) | 1997-06-09 | 2003-04-15 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
FR2852021A1 (en) * | 2003-03-04 | 2004-09-10 | Univ Nice Sophia Antipolis | In cell selection of RNA able to confer a particular phenotype, useful e.g. for imparting resistance to virus or sensitivity to toxin, by transforming cells with a library of random RNA-encoding sequences |
EP1474175A2 (en) * | 2001-05-14 | 2004-11-10 | Immusol Incorporated | Agents that regulate apoptosis |
US7125717B2 (en) | 1999-08-09 | 2006-10-24 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
US9415119B2 (en) | 2009-05-02 | 2016-08-16 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0996741A4 (en) * | 1997-01-23 | 2004-06-09 | Immusol Inc | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
CA2324440A1 (en) * | 1998-03-28 | 1999-10-07 | University Of Utah Research Foundation | Directed antisense libraries |
US8202846B2 (en) | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
JP2003526367A (en) * | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | RNA interference method and RNA interference composition |
US20030084471A1 (en) * | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
AU2003247505A1 (en) * | 2002-06-05 | 2003-12-22 | University Of Iowa Research Foundation | Spliceosome mediated rna trans-splicing in stem cells |
JP2007515172A (en) * | 2003-12-23 | 2007-06-14 | シェーリング コーポレイション | Method for generating a stable A549 cell line in serum-free medium suspension culture |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
US5723289A (en) | 1990-06-11 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | Parallel selex |
US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
US5763566A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
US5712375A (en) | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
ATE160821T1 (en) | 1990-06-11 | 1997-12-15 | Nexstar Pharmaceuticals Inc | NUCLEIC ACID LIGANDS |
US5789157A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
US5750342A (en) | 1990-06-11 | 1998-05-12 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
US5853984A (en) | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5688935A (en) | 1990-06-11 | 1997-11-18 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5864026A (en) | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
AU651380B2 (en) * | 1990-07-16 | 1994-07-21 | University Of Medicine And Dentistry Of New Jersey | Selection of ribozymes that efficiently cleave target RNA |
EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | Method and reagent for inhibiting viral replication. |
US5496698A (en) | 1992-08-26 | 1996-03-05 | Ribozyme Pharmaceuticals, Inc. | Method of isolating ribozyme targets |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
DE69430665T2 (en) * | 1993-01-15 | 2002-11-21 | The Public Health Research Institute Of The City Of New York, Inc. | SENSITIVE NUCLEIC ACID SANDWICH HYBRIDIZATION ASSAY AND KITS |
KR960702518A (en) | 1993-05-17 | 1996-04-27 | 린다 에스, 스티븐슨 | RIBOZYME GENE THERAPY FOR HIV INFECTION AND AIDS |
US5574967A (en) | 1994-01-11 | 1996-11-12 | Ericsson Ge Mobile Communications, Inc. | Waste energy control and management in power amplifiers |
US5580967A (en) | 1994-05-13 | 1996-12-03 | The Scripps Research Institute | Optimized catalytic DNA-cleaving ribozymes |
DE4424762C1 (en) * | 1994-07-04 | 1995-07-27 | Max Planck Gesellschaft | Ribozyme library in optimised expression cassette |
US6107027A (en) * | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
EP0996741A4 (en) * | 1997-01-23 | 2004-06-09 | Immusol Inc | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
-
1998
- 1998-01-21 EP EP98902675A patent/EP0996741A4/en not_active Withdrawn
- 1998-01-21 US US09/355,221 patent/US6605429B1/en not_active Expired - Fee Related
- 1998-01-21 AU AU59275/98A patent/AU5927598A/en not_active Abandoned
- 1998-01-21 CA CA002278734A patent/CA2278734A1/en not_active Abandoned
- 1998-01-21 JP JP53211498A patent/JP2002514914A/en active Pending
- 1998-01-21 WO PCT/US1998/001196 patent/WO1998032880A1/en not_active Application Discontinuation
-
2003
- 2003-07-02 US US10/613,565 patent/US20040096818A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
CAMERON F. H., ET AL.: "SPECIFIC GENE SUPPRESSION BY ENGINEERED RIBOZYMES IN MONKEY CELLS.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 86., 1 December 1989 (1989-12-01), US, pages 9139 - 9143., XP002911041, ISSN: 0027-8424, DOI: 10.1073/pnas.86.23.9139 * |
See also references of EP0996741A4 * |
SIOUD M., ET AL.: "PREFORMED RIBOZYME DESTROYS TUMOUR NECROSIS FACTOR MRNA IN HUMAN CELLS.", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 223., 1 January 1992 (1992-01-01), United Kingdom, pages 831 - 835., XP002911042, ISSN: 0022-2836, DOI: 10.1016/0022-2836(92)90244-E * |
WELCH P. J., ET AL.: "A POTENTIAL THERAPEUTIC APPLICATION OF HAIRPIN RIBOZYMES: IN VITRO AND IN VIVO STUDIES OF GENE THERAPY FOR HEPATITIS C VIRUS INFECTION", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 03., 1 January 1996 (1996-01-01), GB, pages 994 - 1001., XP002911040, ISSN: 0969-7128 * |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050530A3 (en) * | 1997-05-09 | 1999-07-29 | Ribozyme Pharm Inc | Enzymatic nucleic acids: synthesis, selection and use |
WO1998050530A2 (en) * | 1997-05-09 | 1998-11-12 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids: synthesis, selection and use |
US6548657B1 (en) | 1997-06-09 | 2003-04-15 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
US6280936B1 (en) | 1997-06-09 | 2001-08-28 | Ribozyme Pharmaceuticals, Inc. | Method for screening nucleic acid catalysts |
US6448009B1 (en) | 1997-07-03 | 2002-09-10 | Ribozyme Pharmaceuticals, Inc. | Method for target site selection and discovery |
US6183959B1 (en) | 1997-07-03 | 2001-02-06 | Ribozyme Pharmaceuticals, Inc. | Method for target site selection and discovery |
US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
US6797815B2 (en) | 1997-08-22 | 2004-09-28 | Sirna Therapeutics, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
US6489465B2 (en) | 1997-08-22 | 2002-12-03 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
US6509460B1 (en) | 1997-11-05 | 2003-01-21 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6127535A (en) * | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
WO1999027135A2 (en) * | 1997-11-21 | 1999-06-03 | Yale University | Method for identifying and inhibiting functional nucleic acid molecules in cells |
WO1999027135A3 (en) * | 1997-11-21 | 1999-07-29 | Innovir Lab Inc | Method for identifying and inhibiting functional nucleic acid molecules in cells |
WO1999032618A1 (en) * | 1997-12-19 | 1999-07-01 | Strata Biosciences Incorporated | Non-bacterial cloning in delivery and expression of nucleic acids |
WO1999041371A1 (en) * | 1998-02-13 | 1999-08-19 | Genetrace Systems, Inc. | Use of ribozymes for functionating genes |
US6803194B1 (en) | 1998-02-13 | 2004-10-12 | Hk Pharmaceuticals, Inc. | Use of ribozymes for functionating genes |
US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
WO1999053031A2 (en) * | 1998-04-08 | 1999-10-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Process for producing cell clone libraries |
WO1999053031A3 (en) * | 1998-04-08 | 1999-12-16 | Max Planck Gesellschaft | Process for producing cell clone libraries |
WO2000005406A1 (en) * | 1998-07-20 | 2000-02-03 | M & E Biotech A/S | Novel methods for the identification of ligand and target biomolecules |
EP1270746A1 (en) * | 1998-07-20 | 2003-01-02 | Inoxell A/S | Methods for the identification of ligand and target biomolecules |
EP1097244A1 (en) * | 1998-07-22 | 2001-05-09 | Immusol, Inc. | Substantially complete ribozyme libraries |
EP1097244A4 (en) * | 1998-07-22 | 2002-08-07 | Immusol Inc | Substantially complete ribozyme libraries |
WO2000044894A1 (en) * | 1999-01-29 | 2000-08-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for isolating apoptosis-inducing dna sequences and detection system |
WO2000058455A3 (en) * | 1999-03-29 | 2001-01-04 | Michael Blind | Methods for the identification and validation of functional intracellular targets with intramers or in vivo selection |
JP2002539825A (en) * | 1999-03-29 | 2002-11-26 | ブリント,ミヒャエル | Methods for identification and confirmation or in vivo selection of functional intracellular targets with intramers |
WO2000058455A2 (en) * | 1999-03-29 | 2000-10-05 | Michael Blind | Methods for the identification and validation of functional intracellular targets with intramers or in vivo selection |
EP1041144A1 (en) * | 1999-03-29 | 2000-10-04 | Michael Blind | Methods for the identification and validation of functional intracellular targets with intramers or in vivo selection |
WO2000066780A3 (en) * | 1999-04-30 | 2001-12-20 | Univ Florida | Adeno-associated virus-delivered ribozyme compositions and methods of use |
WO2000066780A2 (en) * | 1999-04-30 | 2000-11-09 | University Of Florida | Adeno-associated virus-delivered ribozyme compositions and methods of use |
WO2001000869A3 (en) * | 1999-06-23 | 2001-05-10 | Intelligene Ltd | Arrays of catalytic or pre-catalytic nucleic acids |
WO2001000869A2 (en) * | 1999-06-23 | 2001-01-04 | Intelligene Ltd. | Arrays of catalytic or pre-catalytic nucleic acids |
US7785888B2 (en) | 1999-08-09 | 2010-08-31 | Genzyme Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
US7125717B2 (en) | 1999-08-09 | 2006-10-24 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
US7846729B2 (en) | 1999-08-09 | 2010-12-07 | Genzyme Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
US8093054B2 (en) | 1999-08-09 | 2012-01-10 | Genzyme Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
EP1187845A4 (en) * | 1999-11-12 | 2002-08-28 | Immusol Inc | Tumor suppressor molecules and methods of use |
US6787646B1 (en) | 1999-11-12 | 2004-09-07 | Immusol, Inc. | Tumor suppressor molecules and methods of use |
EP1187845A2 (en) * | 1999-11-12 | 2002-03-20 | Immusol, Inc. | Tumor suppressor molecules and methods of use |
WO2001044513A3 (en) * | 1999-12-16 | 2002-07-04 | Iconix Pharm Inc | Random domain mapping |
US6653075B2 (en) | 1999-12-16 | 2003-11-25 | Iconix Pharmaceuticals, Inc. | Random domain mapping |
WO2001044513A2 (en) * | 1999-12-16 | 2001-06-21 | Iconix Pharmaceuticals, Inc. | Random domain mapping |
WO2001083754A2 (en) * | 2000-05-02 | 2001-11-08 | Immusol, Incorporated | Cellular regulators of infectious agents and methods of use |
WO2001083754A3 (en) * | 2000-05-02 | 2002-10-03 | Immusol Inc | Cellular regulators of infectious agents and methods of use |
US6808876B1 (en) | 2000-05-02 | 2004-10-26 | Immusol, Inc. | Cellular regulators of infectious agents and methods of use |
WO2002063037A3 (en) * | 2001-02-02 | 2003-10-02 | Max Planck Gesellschaft | Method for identifying functional nucleic acids |
AU2002249170B2 (en) * | 2001-02-02 | 2007-02-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V | Method for identifying functional nucleic acids |
WO2002063037A2 (en) * | 2001-02-02 | 2002-08-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying functional nucleic acids |
EP1474175A4 (en) * | 2001-05-14 | 2005-01-19 | Immusol Inc | Agents that regulate apoptosis |
EP1474175A2 (en) * | 2001-05-14 | 2004-11-10 | Immusol Incorporated | Agents that regulate apoptosis |
US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
WO2004080378A3 (en) * | 2003-03-04 | 2005-04-21 | Univ Nice Sophia Antipolis | Methods and tools for screening active rna in cellulo |
WO2004080378A2 (en) * | 2003-03-04 | 2004-09-23 | Biointerference | Methods and tools for screening active rna in cellulo |
FR2852021A1 (en) * | 2003-03-04 | 2004-09-10 | Univ Nice Sophia Antipolis | In cell selection of RNA able to confer a particular phenotype, useful e.g. for imparting resistance to virus or sensitivity to toxin, by transforming cells with a library of random RNA-encoding sequences |
US9415119B2 (en) | 2009-05-02 | 2016-08-16 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US10369193B2 (en) | 2009-05-02 | 2019-08-06 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US11911440B2 (en) | 2009-05-02 | 2024-02-27 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US11975043B2 (en) | 2009-05-02 | 2024-05-07 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
Also Published As
Publication number | Publication date |
---|---|
JP2002514914A (en) | 2002-05-21 |
CA2278734A1 (en) | 1998-07-30 |
EP0996741A1 (en) | 2000-05-03 |
AU5927598A (en) | 1998-08-18 |
US20040096818A1 (en) | 2004-05-20 |
EP0996741A4 (en) | 2004-06-09 |
US6605429B1 (en) | 2003-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6605429B1 (en) | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries | |
AU750598B2 (en) | Substantially complete ribozyme libraries | |
Sullenger et al. | Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication | |
Kennedy et al. | Experiments in transgenic mice show that hepatocytes are the source for postnatal liver growth and do not stream | |
HUT78054A (en) | Mammalian telomerase | |
EP0948513A1 (en) | Delivery construct for antisense nucleic acids and methods of use | |
JPH10507067A (en) | RNA component of telomerase | |
Hauswirth et al. | Ribozyme uses in retinal gene therapy | |
Hargrove et al. | High-level globin gene expression mediated by a recombinant adeno-associated virus genome that contains the 3′ γ globin gene regulatory element and integrates as tandem copies in erythroid cells | |
PAN et al. | A selection system for identifying accessible sites in target RNAs | |
JP2007259871A (en) | Composition and method for mediating cell cycle | |
Lee et al. | mRNA localization signals can enhance the intracellular effectiveness of hammerhead ribozymes | |
JP4908631B2 (en) | Allosteric trans-splicing group I ribozyme whose target-specific RNA replacement activity is regulated by theophylline | |
Ozaki et al. | Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells | |
EP1700914A1 (en) | Development of mammalian genome modification technique using retrotransposon | |
WO1999051755A2 (en) | Ribozyme-mediated control of gene expression | |
US20040259079A1 (en) | Substantially complete ribozyme libraries | |
US6303370B1 (en) | Tissue-specific regulatory elements | |
CA2315242C (en) | Non-bacterial cloning in delivery and expression of nucleic acids | |
CN101495633B (en) | Composition and method for treatment of tumors | |
Prasad Alur et al. | Modification of multiple transcriptional regulatory elements in a Moloney murine leukemia virus gene transfer vector circumvents silencing in fibroblast grafts and increases levels of expression of the transferred enzyme | |
EP1466000B1 (en) | Regulation of gene transcription by the variable number of tandem repeats (vntr) domain of the dopamine transporter gene | |
JP2000508904A (en) | Expression system derived from tyrosine hydroxylase gene | |
Männik et al. | Effective generation of transgenic mice by Bovine papillomavirus type 1 based self-replicating plasmid that is maintained as extrachromosomal genetic element in three generations of animals | |
Shaw et al. | Ribozymes Directed Against Messenger RNAs Associated With Autosomal Dominant Retinitis Pigmentosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2278734 Country of ref document: CA Ref country code: CA Ref document number: 2278734 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09355221 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998902675 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998902675 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998902675 Country of ref document: EP |